HLA-DR-	O
,	O
CD33+	O
,	O
CD56+	O
,	O
CD16-	O
myeloid/natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French-American-British	O
acute	O
myeloid	O
leukemia-M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	B-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33+	O
,	O
CD56+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+/-	O
,	O
HLA-DR	B-protein
-	O
,	O
CD16	B-protein
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	B-protein
(	I-protein
CD33	I-protein
,	I-protein
CD13	I-protein
,	I-protein
CD15	I-protein
)	I-protein
and	I-protein
NK	I-protein
cell-associated	I-protein
(	I-protein
CD56	I-protein
)	I-protein
antigens	I-protein
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B-protein
(	O
neural	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
)	O
in	O
leukemic	B-cell_type
blasts	I-cell_type
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B-protein
,	O
no	O
case	O
expressed	O
CD2	B-protein
,	O
CD3	B-protein
,	O
or	O
CD8	B-protein
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
beta	I-protein
,	I-protein
gamma	I-protein
,	I-protein
delta	I-protein
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B-protein
variant	I-protein
(	O
FAB	B-protein
AML-M3v	I-protein
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic/retinoic	B-RNA
acid	I-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
RAR	I-RNA
alpha	I-RNA
)	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
RT-PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	B-DNA
17q	I-DNA
:	O
1	O
with	O
del	B-DNA
(	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q25	I-DNA
)	I-DNA
and	O
the	O
other	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q23	I-DNA
;	I-DNA
q21	I-DNA
)	I-DNA
and	O
the	O
promyelocytic	B-RNA
leukemia	I-RNA
zinc	I-RNA
finger/RAR	I-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
.	O

All	O
cases	O
tested	O
(	O
6/20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell-mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33+	O
,	O
CD56+	O
,	O
CD16	B-protein
-acute	O
leukemias	O
and	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
NK	I-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD33+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
counterpart	I-cell_type
cell	I-cell_type
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	I-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA-nonresponsive	O
cases	O
from	O
ATRA-responsive	O
true	O
APL	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HLA-DR	NULL
,	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16	NULL
``	NULL
Myeloid/Natural	NULL
Killer	NULL
Cell	NULL
Acute	NULL
Leukemia	NULL
:	NULL
A	NULL
Previously	NULL
Unrecognized	NULL
Form	NULL
of	NULL
Acute	NULL
Leukemia	NULL
Potentially	NULL
Misdiagnosed	NULL
as	NULL
French-	NULL
Acute	NULL
Myeloid	NULL
Leukemia-M3	NULL
By	NULL
Amy	NULL
A.	NULL
Scott	NULL
,	NULL
David	NULL
R.	NULL
Head	NULL
,	NULL
Kenneth	NULL
J.	NULL
Kopecky	NULL
,	NULL
Frederick	NULL
R.	NULL
Appelbaum	NULL
,	NULL
Karl	NULL
S.	NULL
Theil	NULL
,	NULL
Michael	NULL
R.	NULL
Grever	NULL
,	NULL
I-Ming	NULL
Chen	NULL
,	NULL
Michael	NULL
H.	NULL
Whittaker	NULL
,	NULL
Barbara	NULL
B.	NULL
Griffith	NULL
,	NULL
Jonathan	NULL
D.	NULL
Licht	NULL
,	NULL
Samuel	NULL
Waxman	NULL
,	NULL
Margaret	NULL
M.	NULL
Whalen	NULL
,	NULL
Arthur	NULL
D.	NULL
Bankhurst	NULL
,	NULL
Lynn	NULL
C.	NULL
Richter	NULL
,	NULL
Thomas	NULL
M.	NULL
Grogan	NULL
,	NULL
and	NULL
Cheryl	NULL
L.	NULL
Willman	NULL
We	NULL
have	NULL
identified	NULL
and	NULL
characterized	NULL
a	NULL
previously	NULL
unrecognized	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
that	NULL
shares	NULL
features	NULL
of	NULL
both	NULL
myeloid	NULL
and	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
.	NULL

From	NULL
a	NULL
consecutive	NULL
series	NULL
of	NULL
350	NULL
cases	NULL
of	NULL
adult	NULL
de	NULL
novo	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
{	NULL
AML	NULL
}	NULL
,	NULL
we	NULL
identified	NULL
20	NULL
cases	NULL
(	NULL
6	NULL
%	NULL
)	NULL
with	NULL
a	NULL
unique	NULL
immuno-phenotype	NULL
:	NULL
CD33	NULL
,	NULL
CD56®	NULL
,	NULL
CD11a*	NULL
,	NULL
CD13®	NULL
,	NULL
CD15	NULL
``	NULL
,	NULL
CD34*	NULL
,	NULL
HLA-DR~	NULL
,	NULL
CD16	NULL
.	NULL

Multicolor	NULL
flow	NULL
cytometric	NULL
assays	NULL
confirmed	NULL
the	NULL
coexpression	NULL
of	NULL
myeloid	NULL
(	NULL
CD33	NULL
,	NULL
CD13	NULL
,	NULL
CD15	NULL
)	NULL
and	NULL
NK	NULL
cell-associated	NULL
(	NULL
CD56	NULL
)	NULL
antigens	NULL
in	NULL
each	NULL
case	NULL
,	NULL
whereas	NULL
reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
assays	NULL
confirmed	NULL
the	NULL
identity	NULL
of	NULL
CD56	NULL
(	NULL
neural	NULL
cell	NULL
adhesion	NULL
molecule	NULL
)	NULL
in	NULL
leukemic	NULL
blasts	NULL
.	NULL

Although	NULL
two	NULL
cases	NULL
expressed	NULL
CD4	NULL
,	NULL
no	NULL
case	NULL
expressed	NULL
CD2	NULL
,	NULL
CD3	NULL
,	NULL
or	NULL
CD8	NULL
and	NULL
no	NULL
case	NULL
showed	NULL
clonal	NULL
rearrangement	NULL
of	NULL
genes	NULL
encoding	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
B	NULL
,	NULL
y	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Leukemic	NULL
blasts	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
cases	NULL
shared	NULL
unique	NULL
morphologic	NULL
features	NULL
(	NULL
deeply	NULL
invaginated	NULL
nuclear	NULL
membranes	NULL
,	NULL
scant	NULL
cytoplasm	NULL
with	NULL
fine	NULL
azurophilic	NULL
granularity	NULL
,	NULL
and	NULL
finely	NULL
granular	NULL
Sudan	NULL
black	NULL
B	NULL
and	NULL
my-eloperoxidase	NULL
cytochemical	NULL
reactivity	NULL
)	NULL
that	NULL
were	NULL
remarkably	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
;	NULL
particularly	NULL
the	NULL
microgranular	NULL
variant	NULL
(	NULL
FAB	NULL
AML-M3v	NULL
)	NULL
.	NULL

However	NULL
,	NULL
all	NULL
20	NULL
cases	NULL
lacked	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
17	NULL
cases	NULL
tested	NULL
lacked	NULL
the	NULL
promyelocytic/retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
CUTE	NULL
MYELOID	NULL
LEUKEMIA	NULL
(	NULL
AML	NULL
)	NULL
constitutes	NULL
a	NULL
heterogeneous	NULL
group	NULL
of	NULL
leukemic	NULL
disorders	NULL
with	NULL
diverse	NULL
biologic	NULL
and	NULL
clinical	NULL
features	NULL
.	NULL

Traditionally	NULL
,	NULL
AML	NULL
has	NULL
been	NULL
classified	NULL
by	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
criteria	NULL
,	NULL
From	NULL
the	NULL
University	NULL
of	NULL
New	NULL
Mexico	NULL
(	NULL
UNM	NULL
)	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Departments	NULL
of	NULL
Pathology	NULL
,	NULL
Medicine	NULL
,	NULL
and	NULL
the	NULL
UNM	NULL
Cancer	NULL
Center	NULL
,	NULL
Center	NULL
for	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Diagnostics	NULL
,	NULL
Albuquerque	NULL
,	NULL
NM	NULL
;	NULL
The	NULL
Southwest	NULL
Oncology	NULL
Group	NULL
(	NULL
SWOG	NULL
)	NULL
Leukemia	NULL
Biology	NULL
Pro-gram	NULL
,	NULL
San	NULL
Antonio	NULL
,	NULL
TX	NULL
;	NULL
St	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Memphis	NULL
,	NULL
TN	NULL
;	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
;	NULL
The	NULL
Ohio	NULL
State	NULL
University	NULL
,	NULL
Departments	NULL
of	NULL
Pathology	NULL
and	NULL
Medicine	NULL
,	NULL
Columbus	NULL
,	NULL
OH	NULL
;	NULL
The	NULL
Mount	NULL
Sinai	NULL
Medical	NULL
Center	NULL
,	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
;	NULL
The	NULL
University	NULL
of	NULL
Arizona	NULL
and	NULL
the	NULL
SWOG	NULL
Lymphoma	NULL
Biology	NULL
Repository	NULL
,	NULL
Tucson	NULL
,	NULL
AZ	NULL
.	NULL

Submitted	NULL
October	NULL
6	NULL
,	NULL
1993	NULL
;	NULL
accepted	NULL
March	NULL
8	NULL
,	NULL
1994	NULL
.	NULL

Supported	NULL
by	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
Grants	NULL
No	NULL
.	NULL

CA32102	NULL
,	NULL
CA32734	NULL
(	NULL
both	NULL
supporting	NULL
the	NULL
SWOG	NULL
Leukemia	NULL
and	NULL
Lymphoma	NULL
Biology	NULL
Programs	NULL
)	NULL
,	NULL
and	NULL
€A59936	NULL
(	NULL
supporting	NULL
S.W	NULL
.	NULL

and	NULL
J.D.L	NULL
.	NULL
)	NULL

;	NULL
AAS	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
Clinical	NULL
Oncology	NULL
Fellowship	NULL
Award	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
(	NULL
No	NULL
.	NULL

93-138-1	NULL
)	NULL
.	NULL

Presented	NULL
in	NULL
part	NULL
at	NULL
the	NULL
82nd	NULL
annual	NULL
meeting	NULL
of	NULL
the	NULL
United	NULL
States	NULL
and	NULL
Canadian	NULL
Academy	NULL
of	NULL
Pathology	NULL
in	NULL
New	NULL
Orleans	NULL
,	NULL
LA	NULL
,	NULL
March	NULL
16	NULL
,	NULL
1993	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
SWOG	NULL
Operations	NULL
Office	NULL
,	NULL
14980	NULL
Omi-cron	NULL
Dr	NULL
,	NULL
San	NULL
Antonio	NULL
,	NULL
TX	NULL
78245-3218	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1994	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-497	NULL
1/94/8401-0026	NULL
$	NULL
3.00/0	NULL
244	NULL
fusion	NULL
transcript	NULL
in	NULL
RT-PCR	NULL
assays	NULL
;	NULL
12	NULL
cases	NULL
had	NULL
46	NULL
,	NULL
XX	NULL
or	NULL
46	NULL
,	NULL
XY	NULL
karyotypes	NULL
,	NULL
whereas	NULL
2	NULL
cases	NULL
had	NULL
abnormalities	NULL
of	NULL
chromosome	NULL
17q	NULL
:	NULL
1	NULL
with	NULL
del	NULL
{	NULL
17	NULL
)	NULL
(	NULL
q25	NULL
)	NULL
and	NULL
the	NULL
other	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
}	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
and	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
zinc	NULL
finger/RARa	NULL
«	NULL
fusion	NULL
transcript	NULL
.	NULL

All	NULL
cases	NULL
tested	NULL
(	NULL
6/20	NULL
)	NULL
,	NULL
including	NULL
the	NULL
case	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
,	NULL
failed	NULL
to	NULL
differentiate	NULL
in	NULL
vitro	NULL
in	NULL
response	NULL
to	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
cases	NULL
may	NULL
account	NULL
for	NULL
some	NULL
APLs	NULL
that	NULL
have	NULL
not	NULL
shown	NULL
a	NULL
clinical	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

Four	NULL
of	NULL
6	NULL
cases	NULL
tested	NULL
showed	NULL
functional	NULL
NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
,	NULL
suggesting	NULL
a	NULL
relationship	NULL
between	NULL
these	NULL
unique	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
acute	NULL
leukemias	NULL
and	NULL
normal	NULL
CD56	NULL
,	NULL
CD16~	NULL
NK	NULL
precursor	NULL
cells	NULL
.	NULL

Using	NULL
a	NULL
combination	NULL
of	NULL
panning	NULL
and	NULL
multiparameter	NULL
flow	NULL
cytometric	NULL
sorting	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
normal	NULL
CD56*	NULL
,	NULL
CD33*	NULL
,	NULL
CD16~	NULL
counterpart	NULL
cell	NULL
at	NULL
a	NULL
frequency	NULL
of	NULL
1	NULL
%	NULL
to	NULL
2	NULL
%	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
individuals	NULL
.	NULL

Our	NULL
studies	NULL
suggest	NULL
that	NULL
this	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
may	NULL
arise	NULL
from	NULL
transformation	NULL
of	NULL
a	NULL
precursor	NULL
cell	NULL
common	NULL
to	NULL
both	NULL
the	NULL
myeloid	NULL
and	NULL
NK	NULL
cell	NULL
lineages	NULL
;	NULL
thus	NULL
we	NULL
propose	NULL
the	NULL
designation	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
.	NULL

Recognition	NULL
of	NULL
this	NULL
new	NULL
leukemic	NULL
entity	NULL
will	NULL
be	NULL
important	NULL
in	NULL
distinguishing	NULL
these	NULL
ATRA-nonresponsive	NULL
cases	NULL
from	NULL
ATRA-responsive	NULL
true	NULL
APL	NULL
.	NULL

©	NULL
1994	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

formalized	NULL
in	NULL
the	NULL
French-American-British	NULL
(	NULL
FAB	NULL
)	NULL
classification	NULL
system	NULL
.	NULL
'	NULL

''	NULL
However	NULL
,	NULL
more	NULL
recent	NULL
analyses	NULL
of	NULL
the	NULL
immunophenotypic	NULL
,	NULL
cytogenetic	NULL
,	NULL
molecular	NULL
,	NULL
and	NULL
cellular	NULL
features	NULL
of	NULL
AML	NULL
blasts	NULL
have	NULL
identified	NULL
unique	NULL
biologic	NULL
subsets	NULL
of	NULL
AML	NULL
.	NULL
``	NULL

Assessment	NULL
of	NULL
these	NULL
biologic	NULL
parameters	NULL
is	NULL
now	NULL
allowing	NULL
for	NULL
more	NULL
precise	NULL
diagnosis	NULL
,	NULL
classification	NULL
,	NULL
and	NULL
more	NULL
accurate	NULL
prognostication	NULL
of	NULL
AML	NULL
patients	NULL
;	NULL
moreover	NULL
,	NULL
these	NULL
biologic	NULL
and	NULL
genetic	NULL
parameters	NULL
are	NULL
beginning	NULL
to	NULL
have	NULL
a	NULL
significant	NULL
impact	NULL
on	NULL
therapeutic	NULL
decision	NULL
making	NULL
.	NULL
``	NULL

''	NULL
From	NULL
a	NULL
series	NULL
of	NULL
350	NULL
consecutive	NULL
adult	NULL
de	NULL
novo	NULL
AML	NULL
patients	NULL
(	NULL
initially	NULL
identified	NULL
by	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
criteria	NULL
)	NULL
who	NULL
were	NULL
candidates	NULL
for	NULL
Southwest	NULL
Oncology	NULL
Group	NULL
(	NULL
SWOG	NULL
)	NULL
treatment	NULL
protocols	NULL
,	NULL
we	NULL
identified	NULL
20	NULL
cases	NULL
of	NULL
a	NULL
previously	NULL
unrecognized	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
.	NULL

These	NULL
20	NULL
cases	NULL
were	NULL
distinguished	NULL
by	NULL
their	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
by	NULL
their	NULL
unusual	NULL
coexpression	NULL
of	NULL
myeloid	NULL
and	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cell-associated	NULL
antigens	NULL
.	NULL

Although	NULL
the	NULL
morphologic	NULL
features	NULL
of	NULL
these	NULL
cases	NULL
were	NULL
inconsistently	NULL
classified	NULL
by	NULL
submitting	NULL
SWOG	NULL
institutions	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
cases	NULL
were	NULL
noted	NULL
upon	NULL
review	NULL
to	NULL
bear	NULL
a	NULL
striking	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
resemblance	NULL
to	NULL
AML	NULL
cases	NULL
of	NULL
the	NULL
FAB-M3	NULL
subtype	NULL
,	NULL
particularly	NULL
the	NULL
microgranular	NULL
variant	NULL
(	NULL
M3v	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
fully	NULL
characterize	NULL
the	NULL
morphologic	NULL
,	NULL
immunophenotypic	NULL
,	NULL
cytogenetic	NULL
,	NULL
molecular	NULL
,	NULL
and	NULL
biologic	NULL
features	NULL
of	NULL
this	NULL
unique	NULL
type	NULL
of	NULL
acute	NULL
leukemia	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
these	NULL
leukemia	NULL
cases	NULL
show	NULL
functional	NULL
NK	NULL
cell-type	NULL
mediated	NULL
cytotoxicity	NULL
and	NULL
our	NULL
identification	NULL
of	NULL
a	NULL
normal	NULL
myeloid/NK	NULL
counterpart	NULL
cell	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
individuals	NULL
suggest	NULL
that	NULL
this	NULL
unique	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
may	NULL
arise	NULL
from	NULL
transformation	NULL
of	NULL
a	NULL
precursor	NULL
cell	NULL
common	NULL
to	NULL
the	NULL
myeloid	NULL
and	NULL
NK	NULL
cell	NULL
lineages	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
84	NULL
,	NULL
No	NULL
1	NULL
(	NULL
July	NULL
1	NULL
)	NULL
,	NULL
1994	NULL
:	NULL
pp	NULL
244-255	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Sample	NULL
acquisition	NULL
and	NULL
morphologic	NULL
review	NULL
.	NULL

This	NULL
study	NULL
was	NULL
based	NULL
on	NULL
specimens	NULL
of	NULL
bone	NULL
marrow	NULL
(	NULL
BM	NULL
)	NULL
or	NULL
peripheral	NULL
blood	NULL
(	NULL
PB	NULL
)	NULL
submitted	NULL
to	NULL
the	NULL
SWOG	NULL
Reference	NULL
Laboratory	NULL
and	NULL
Myeloid	NULL
Repository	NULL
at	NULL
the	NULL
UNM	NULL
Cancer	NULL
Center	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
of	NULL
SWOG	NULL
.	NULL

Briefly	NULL
,	NULL
pretreatment	NULL
specimens	NULL
of	NULL
BM	NULL
and/or	NULL
PB	NULL
are	NULL
submitted	NULL
to	NULL
the	NULL
Repository	NULL
for	NULL
patients	NULL
who	NULL
are	NULL
candidates	NULL
for	NULL
SWOG	NULL
AML	NULL
treatment	NULL
studies	NULL
.	NULL

Upon	NULL
initial	NULL
receipt	NULL
,	NULL
leukemic	NULL
blasts	NULL
are	NULL
enriched	NULL
on	NULL
Ficoll-Hypaque	NULL
gradients	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
the	NULL
leukemic	NULL
blast	NULL
percentage	NULL
is	NULL
determined	NULL
by	NULL
analysis	NULL
of	NULL
Wright-stained	NULL
cytospins	NULL
.	NULL

All	NULL
cases	NULL
are	NULL
immediately	NULL
analyzed	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
hematopoietic	NULL
cell	NULL
surface	NULL
antigens	NULL
using	NULL
multicolor	NULL
flow	NULL
cytometry	NULL
.	NULL

Residual	NULL
leukemic	NULL
cells	NULL
are	NULL
cryopreserved	NULL
as	NULL
sterile	NULL
,	NULL
viable	NULL
cell	NULL
suspensions	NULL
at	NULL
-135°C	NULL
;	NULL
these	NULL
cryopreserved	NULL
specimens	NULL
were	NULL
used	NULL
for	NULL
the	NULL
additional	NULL
biologic	NULL
assays	NULL
undertaken	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Pretreatment	NULL
Wright-stained	NULL
BM	NULL
aspirates	NULL
and	NULL
PB	NULL
specimens	NULL
as	NULL
well	NULL
as	NULL
a	NULL
panel	NULL
of	NULL
submitted	NULL
or	NULL
centrally	NULL
performed	NULL
cytochemical	NULL
stains	NULL
(	NULL
Sudan	NULL
black	NULL
B	NULL
[	NULL
SBB	NULL
]	NULL
,	NULL
alpha	NULL
napthyl	NULL
butyrate	NULL
esterase	NULL
,	NULL
my-eloperoxidase	NULL
[	NULL
MPO	NULL
]	NULL
,	NULL
and	NULL
chloracetate	NULL
esterase	NULL
)	NULL
were	NULL
reviewed	NULL
by	NULL
members	NULL
of	NULL
the	NULL
SWOG	NULL
Leukemia	NULL
Review	NULL
Panel	NULL
.	NULL

Additional	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
studies	NULL
were	NULL
also	NULL
performed	NULL
on	NULL
air-dried	NULL
aspirates	NULL
and	NULL
on	NULL
thawed	NULL
,	NULL
previously	NULL
cryopreserved	NULL
cell	NULL
suspensions	NULL
and	NULL
were	NULL
reviewed	NULL
by	NULL
three	NULL
of	NULL
the	NULL
authors	NULL
(	NULL
A.S.	NULL
,	NULL
D.H.	NULL
,	NULL
C.W	NULL
.	NULL
)	NULL

and	NULL
Dr	NULL
Kathy	NULL
Foucar	NULL
(	NULL
University	NULL
of	NULL
New	NULL
Mexico	NULL
,	NULL
Albuquerque	NULL
,	NULL
NM	NULL
)	NULL
.	NULL

All	NULL
cases	NULL
were	NULL
classified	NULL
using	NULL
standard	NULL
FAB	NULL
criteria	NULL
and	NULL
were	NULL
alternatively	NULL
classified	NULL
as	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
if	NULL
they	NULL
had	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
reproducible	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
different	NULL
from	NULL
those	NULL
detailed	NULL
in	NULL
the	NULL
current	NULL
FAB	NULL
classification	NULL
system	NULL
(	NULL
see	NULL
Results	NULL
)	NULL
.	NULL

``	NULL
*	NULL
Three	NULL
cases	NULL
reported	NULL
in	NULL
this	NULL
study	NULL
were	NULL
ultimately	NULL
not	NULL
registered	NULL
on	NULL
a	NULL
SWOG	NULL
clinical	NULL
trial	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
Cases	NULL
12	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
)	NULL
;	NULL
however	NULL
,	NULL
slides	NULL
from	NULL
each	NULL
case	NULL
were	NULL
submitted	NULL
by	NULL
SWOG	NULL
institutional	NULL
pathologists	NULL
and	NULL
underwent	NULL
an	NULL
identical	NULL
process	NULL
of	NULL
morphologic	NULL
review	NULL
.	NULL

Immunophenotypic/flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

The	NULL
cell	NULL
surface	NULL
antigen	NULL
profile	NULL
of	NULL
leukemic	NULL
blasts	NULL
in	NULL
each	NULL
case	NULL
initially	NULL
were	NULL
determined	NULL
on	NULL
fresh	NULL
cells	NULL
at	NULL
the	NULL
time	NULL
of	NULL
sample	NULL
submission	NULL
using	NULL
standard	NULL
two-color	NULL
flow	NULL
cytometric	NULL
analysis	NULL
with	NULL
a	NULL
panel	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
MoAbs	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*	NULL
The	NULL
mononuclear	NULL
cell	NULL
component	NULL
after	NULL
Ficoll-Hypaque	NULL
gradient	NULL
separation	NULL
was	NULL
washed	NULL
,	NULL
then	NULL
incubated	NULL
in	NULL
staining	NULL
media	NULL
with	NULL
directly-conjugated	NULL
[	NULL
either	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
or	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
]	NULL
MoAbs	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
[	NULL
Leu19	NULL
(	NULL
CD56	NULL
)	NULL
,	NULL
MY10	NULL
(	NULL
CD34	NULL
)	NULL
,	NULL
LeuM1	NULL
(	NULL
CD15	NULL
)	NULL
,	NULL
Leul	NULL
la	NULL
(	NULL
CD16	NULL
)	NULL
,	NULL
Leul2	NULL
(	NULL
CD19	NULL
)	NULL
,	NULL
Leu16	NULL
(	NULL
CD20	NULL
)	NULL
,	NULL
LeuSb	NULL
(	NULL
CD2	NULL
)	NULL
,	NULL
CRI	NULL
(	NULL
CD35	NULL
)	NULL
,	NULL
CDIlla	NULL
,	NULL
LeuMS	NULL
(	NULL
CD11c	NULL
)	NULL
,	NULL
Gpllb/HMa	NULL
(	NULL
CD41	NULL
)	NULL
,	NULL
Leu	NULL
5b	NULL
(	NULL
CD2	NULL
)	NULL
,	NULL
Leud	NULL
(	NULL
CD3	NULL
)	NULL
,	NULL
and	NULL
HLA-DR	NULL
(	NULL
all	NULL
supplied	NULL
by	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
and	NULL
MY9	NULL
(	NULL
CD33	NULL
)	NULL
,	NULL
MY4	NULL
(	NULL
CDw14	NULL
)	NULL
,	NULL
and	NULL
MY7	NULL
(	NULL
CD13	NULL
)	NULL
(	NULL
all	NULL
supplied	NULL
by	NULL
Coulter	NULL
,	NULL
Inc	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
]	NULL
.	NULL

Background	NULL
staining	NULL
was	NULL
determined	NULL
using	NULL
isotype	NULL
controls	NULL
(	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
IgG1	NULL
and	NULL
PE-conjugated	NULL
IgG2	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
samples	NULL
were	NULL
analyzed	NULL
immediately	NULL
with	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
.	NULL

Although	NULL
the	NULL
percent	NULL
viability	NULL
of	NULL
both	NULL
fresh	NULL
and	NULL
thawed	NULL
,	NULL
previously	NULL
cryopreserved	NULL
leukemic	NULL
cell	NULL
suspensions	NULL
usually	NULL
exceeded	NULL
90	NULL
%	NULL
,	NULL
dead	NULL
cells	NULL
were	NULL
excluded	NULL
from	NULL
flow	NULL
cytometric	NULL
analysis	NULL
with	NULL
propidium	NULL
iodide	NULL
gating	NULL
.	NULL
``	NULL

Flow	NULL
cytometric	NULL
data	NULL
were	NULL
analyzed	NULL
with	NULL
FACScan	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
and	NULL
results	NULL
expressed	NULL
as	NULL
units	NULL
of	NULL
mean	NULL
channel	NULL
fluorescence	NULL
shift	NULL
relative	NULL
to	NULL
background	NULL
control	NULL
levels	NULL
;	NULL
composite	NULL
two-color	NULL
dot	NULL
plots	NULL
and	NULL
contour	NULL
plots	NULL
were	NULL
generated	NULL
using	NULL
the	NULL
Lyses	NULL
II	NULL
analysis	NULL
system	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Cytogenetic	NULL
analysis	NULL
.	NULL

-	NULL
Pretreatment	NULL
BM	NULL
and/or	NULL
PB	NULL
samples	NULL
were	NULL
prepared	NULL
for	NULL
cytogenetic	NULL
analysis	NULL
by	NULL
direct	NULL
and/or	NULL
short	NULL
term	NULL
(	NULL
24	NULL
to	NULL
72	NULL
hour	NULL
)	NULL
unstimulated	NULL
cultures	NULL
at	NULL
approved	NULL
SWOG	NULL
cytogenetics	NULL
laboratories	NULL
.	NULL
``	NULL

A	NULL
minimum	NULL
of	NULL
20	NULL
G-banded	NULL
metaphases	NULL
were	NULL
analyzed	NULL
in	NULL
each	NULL
case	NULL
,	NULL
and	NULL
chromosomes	NULL
were	NULL
identified	NULL
and	NULL
clonal	NULL
abnormalities	NULL
classified	NULL
according	NULL
to	NULL
the	NULL
International	NULL
System	NULL
for	NULL
245	NULL
Table	NULL
1	NULL
.	NULL

Morphologic	NULL
,	NULL
immunophenotypic	NULL
,	NULL
and	NULL
Cytogenetic	NULL
Characteristics	NULL
of	NULL
Myeloid/NK	NULL
Precursor	NULL
Cell	NULL
Leukemia	NULL
Cases	NULL
Case	NULL
No	NULL
.	NULL

-	NULL
FAB*	NULL
Immunophenctype	NULL
Karyotype	NULL
1	NULL
M7	NULL
47	NULL
,	NULL
XY	NULL
,	NULL
+8,1	NULL
(	NULL
16	NULL
;	NULL
21	NULL
)	NULL
(	NULL
p11	NULL
;	NULL
422	NULL
)	NULL
2	NULL
-	NULL
My/NK	NULL
HLA-DR7	NULL
,	NULL
CD34*	NULL
,	NULL
CD33®	NULL
,	NULL
CD15*	NULL
CD13+	NULL
,	NULL
CD56®	NULL
,	NULL
CD167	NULL
,	NULL
CD11a¢	NULL
46	NULL
,	NULL
XY	NULL
3	NULL
M1	NULL
HLA-DR~	NULL
,	NULL
CD34+	NULL
,	NULL
CD33	NULL
,	NULL
CD15*	NULL
CD13+	NULL
,	NULL
CD56*	NULL
,	NULL
CD167	NULL
,	NULL
CD11a¢	NULL
ND	NULL
4	NULL
-	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD34®	NULL
,	NULL
CD33+	NULL
,	NULL
CD15*	NULL
CD13+	NULL
,	NULL
CD56®	NULL
,	NULL
CD167	NULL
,	NULL
CD1Ma®	NULL
46	NULL
,	NULL
XX	NULL
5	NULL
-	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
46	NULL
,	NULL
XY	NULL
6	NULL
-	NULL
My/NK	NULL
HLA-DR7	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
CD13+	NULL
,	NULL
CD56*	NULL
,	NULL
CD167	NULL
,	NULL
CD11a*	NULL
46	NULL
,	NULL
XX	NULL
7	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD34~	NULL
,	NULL
CD33*	NULL
ND	NULL
8	NULL
M2	NULL
HLA-DR~	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
CD13+	NULL
,	NULL
CD56+	NULL
,	NULL
CD167	NULL
,	NULL
CD11a+°	NULL
46	NULL
,	NULL
XY	NULL
9	NULL
-	NULL
My/NK	NULL
HLA-DRT	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
CD13®	NULL
,	NULL
CD56	NULL
,	NULL
CD167	NULL
,	NULL
CD11a®	NULL
,	NULL
CD4*	NULL
_	NULL
46	NULL
,	NULL
XX	NULL
HLA-DR~	NULL
,	NULL
CD34~	NULL
,	NULL
CD33*	NULL
CD13®	NULL
,	NULL
CD56*	NULL
,	NULL
CD167	NULL
,	NULL
CD11a	NULL
%	NULL
,	NULL
CD4¢	NULL
10	NULL
M2	NULL
45	NULL
,	NULL
XY¥	NULL
,	NULL
-11	NULL
,	NULL
~14	NULL
,	NULL
-17	NULL
,	NULL
-22	NULL
,	NULL
+i	NULL
(	NULL
17q	NULL
)	NULL
,	NULL
+der	NULL
(	NULL
22	NULL
)	NULL
t	NULL
(	NULL
?	NULL

17	NULL
;	NULL
22	NULL
)	NULL
(	NULL
p11	NULL
;	NULL
p11	NULL
}	NULL
/44	NULL
,	NULL
idem	NULL
,	NULL
-20	NULL
,	NULL
der	NULL
(	NULL
11	NULL
)	NULL
t	NULL
(	NULL
11	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q11	NULL
)	NULL
11	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
CD13-	NULL
,	NULL
CD56	NULL
,	NULL
CD16~	NULL
46	NULL
,	NULL
XY	NULL
12	NULL
M2	NULL
HLA-DR~	NULL
,	NULL
CD34~	NULL
,	NULL
CD33*	NULL
CD13-	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
46	NULL
,	NULL
XY	NULL
13	NULL
-	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD34~	NULL
,	NULL
CD33*	NULL
CD13~	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
ND	NULL
14	NULL
My/NK	NULL
CD13-	NULL
,	NULL
CD56®	NULL
,	NULL
CD16~	NULL
46	NULL
,	NULL
XY	NULL
15	NULL
-	NULL
My/NK	NULL
HLA-DR7	NULL
,	NULL
CD347	NULL
,	NULL
CD33~	NULL
CD13+	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
46	NULL
,	NULL
XX	NULL
,	NULL
del17	NULL
(	NULL
q25	NULL
)	NULL
16	NULL
M2	NULL
HLA-DR~	NULL
,	NULL
CD34~	NULL
,	NULL
CD33+*	NULL
CD13+	NULL
,	NULL
CD56®	NULL
,	NULL
CD16~	NULL
46XX	NULL
,	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
17	NULL
My/NK	NULL
HLA-DRZ	NULL
,	NULL
CD347	NULL
,	NULL
CD33~	NULL
46	NULL
,	NULL
XX	NULL
18	NULL
-	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD347	NULL
,	NULL
CD33~	NULL
CD13+	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
46	NULL
,	NULL
XY	NULL
19	NULL
M2	NULL
HLA-DR~	NULL
,	NULL
CD34*	NULL
,	NULL
CD33*	NULL
CD13+	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
ND	NULL
20	NULL
-	NULL
My/NK	NULL
HLA-DR~	NULL
,	NULL
CD347	NULL
,	NULL
CD33*	NULL
CD56®	NULL
,	NULL
CD16~	NULL
47	NULL
,	NULL
XX	NULL
,	NULL
+8	NULL
,	NULL
del	NULL
(	NULL
13	NULL
)	NULL
(	NULL
41729174	NULL
)	NULL
Positivity	NULL
is	NULL
defined	NULL
as	NULL
greater	NULL
than	NULL
20	NULL
%	NULL
of	NULL
fluorescence	NULL
intensity	NULL
compared	NULL
with	NULL
the	NULL
background	NULL
isotope	NULL
control	NULL
fluorescence	NULL
intensity	NULL
.	NULL

Abbreviations	NULL
:	NULL
My/NK	NULL
,	NULL
myeloid/natural	NULL
killer	NULL
call	NULL
morphologic	NULL
features	NULL
;	NULL
idem	NULL
,	NULL
same	NULL
as	NULL
previous	NULL
clone	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
or	NULL
unsuccessful	NULL
.	NULL

*elf	NULL
morphologic	NULL
features	NULL
were	NULL
consistent	NULL
with	NULL
a	NULL
particular	NULL
FAB	NULL
subtype	NULL
,	NULL
then	NULL
that	NULL
subtype	NULL
is	NULL
provided	NULL
.	NULL

Alternatively	NULL
,	NULL
if	NULL
features	NULL
were	NULL
most	NULL
consistent	NULL
with	NULL
the	NULL
myeloid/NK	NULL
(	NULL
My/NK	NULL
)	NULL
subtype	NULL
,	NULL
then	NULL
that	NULL
designation	NULL
is	NULL
provided	NULL
.	NULL

Human	NULL
Cytogenetic	NULL
Nomenclature	NULL
(	NULL
ISCN	NULL
)	NULL
(	NULL
1985	NULL
)	NULL
and	NULL
ISCN	NULL
Representative	NULL
original	NULL
karyotypes	NULL
were	NULL
submitted	NULL
for	NULL
central	NULL
review	NULL
to	NULL
the	NULL
SWOG	NULL
Cytogenetics	NULL
Working	NULL
Group	NULL
(	NULL
R.	NULL
Ellen	NULL
Magenis	NULL
,	NULL
Chair	NULL
)	NULL
and	NULL
were	NULL
rereviewed	NULL
by	NULL
one	NULL
of	NULL
us	NULL
(	NULL
K.T	NULL
.	NULL
)	NULL

.	NULL

Reverse-transcriptase	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
and	NULL
oligonucleotide	NULL
probe	NULL
hybridization	NULL
assays	NULL
for	NULL
CD56	NULL
neural	NULL
cell	NULL
adhesion	NULL
molecule	NULL
(	NULL
NCAM	NULL
)	NULL
.	NULL

-	NULL
To	NULL
detect	NULL
CD56	NULL
NCAM	NULL
transcripts	NULL
in	NULL
leukemic	NULL
blasts	NULL
,	NULL
RT-PCR	NULL
assays	NULL
were	NULL
performed	NULL
on	NULL
total	NULL
RNA	NULL
isolated	NULL
from	NULL
cases	NULL
8	NULL
and	NULL
15	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

The	NULL
CD56*	NULL
myeloma	NULL
cell	NULL
line	NULL
8226/Dox40	NULL
was	NULL
used	NULL
as	NULL
a	NULL
high-level	NULL
positive	NULL
control	NULL
.	NULL
``	NULL

''	NULL
RNA	NULL
from	NULL
a	NULL
case	NULL
of	NULL
AML	NULL
that	NULL
was	NULL
not	NULL
a	NULL
myeloid/	NULL
NK	NULL
leukemia	NULL
case	NULL
and	NULL
that	NULL
exhibited	NULL
1	NULL
%	NULL
expression	NULL
of	NULL
CD56	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Briefly	NULL
,	NULL
cDNA	NULL
was	NULL
synthesized	NULL
from	NULL
1	NULL
pg	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
in	NULL
20	NULL
gL	NULL
of	NULL
a	NULL
solution	NULL
containing	NULL
5	NULL
mmol/L	NULL
MgC1	NULL
,	NULL
,	NULL
50	NULL
mmol/L	NULL
KCL	NULL
,	NULL
10	NULL
mmol/L	NULL
TRIS-HCL	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
,	NULL
20	NULL
U	NULL
RNase	NULL
inhibitor	NULL
,	NULL
50	NULL
U	NULL
reverse	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

246	NULL
transcriptase	NULL
,	NULL
0.75	NULL
umol/L	NULL
of	NULL
downstream	NULL
primer	NULL
,	NULL
and	NULL
1	NULL
mmol/L	NULL
of	NULL
each	NULL
deoxynucleotide	NULL
triphosphate	NULL
(	NULL
dNTP	NULL
)	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
thermal	NULL
cycler	NULL
(	NULL
Perkin	NULL
Elmer-Cetus	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
at	NULL
42°C	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
99°C	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

To	NULL
amplify	NULL
the	NULL
cDNA	NULL
,	NULL
55	NULL
of	NULL
a	NULL
PCR	NULL
master	NULL
mix	NULL
was	NULL
added	NULL
to	NULL
each	NULL
tube	NULL
to	NULL
yield	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
2	NULL
mmol/L	NULL
MgC1	NULL
;	NULL
,	NULL
50	NULL
mmol/L	NULL
KCI	NULL
,	NULL
and	NULL
10	NULL
mmol/L	NULL
TRIS-HC	NULL
!	NULL

I	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
,	NULL
along	NULL
with	NULL
one	NULL
Ampliwax	NULL
PCR	NULL
Gem	NULL
(	NULL
Perkin	NULL
Elmer-Cetus	NULL
)	NULL
to	NULL
enable	NULL
hot-start	NULL
PCR	NULL
.	NULL

Tubes	NULL
were	NULL
heated	NULL
to	NULL
70°C	NULL
for	NULL
3	NULL
minutes	NULL
and	NULL
cooled	NULL
to	NULL
15°C	NULL
for	NULL
3	NULL
minutes	NULL
.	NULL

A	NULL
final	NULL
25	NULL
uL	NULL
volume	NULL
of	NULL
PCR	NULL
mix	NULL
that	NULL
now	NULL
included	NULL
Amplitaq	NULL
DNA	NULL
polymerase	NULL
(	NULL
2.5	NULL
U/100	NULL
uL	NULL
)	NULL
and	NULL
the	NULL
upstream	NULL
primer	NULL
(	NULL
final	NULL
concentration	NULL
=	NULL
0.15	NULL
pmol/L	NULL
)	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
for	NULL
45	NULL
cycles	NULL
as	NULL
follows	NULL
:	NULL
1	NULL
cycle	NULL
at	NULL
95°C	NULL
for	NULL
3	NULL
minutes	NULL
,	NULL
60°C	NULL
for	NULL
3	NULL
minutes	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
3	NULL
minutes	NULL
;	NULL
43	NULL
cycles	NULL
at	NULL
45	NULL
seconds	NULL
at	NULL
95°C	NULL
,	NULL
1	NULL
minute	NULL
at	NULL
60°C	NULL
,	NULL
and	NULL
1	NULL
minute	NULL
at	NULL
72°C	NULL
;	NULL
and	NULL
finally	NULL
,	NULL
1	NULL
cycle	NULL
of	NULL
95°C	NULL
for	NULL
45	NULL
seconds	NULL
,	NULL
60°C	NULL
for	NULL
1	NULL
minute	NULL
and	NULL
72°C	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
The	NULL
NCAM	NULL
primers	NULL
yielding	NULL
a	NULL
493-bp	NULL
product	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
upstream	NULL
primer	NULL
,	NULL
5-GCCCATCCTCAA-ATACAAAGC-3	NULL
'	NULL
(	NULL
NCAM	NULL
residues	NULL
1,684	NULL
through	NULL
1,704	NULL
)	NULL
,	NULL
and	NULL
downstream	NULL
primer	NULL
,	NULL
5-GGTCCTGAACACAAAATGAGC-3	NULL
'	NULL
(	NULL
NCAM	NULL
residues	NULL
2,156	NULL
through	NULL
2,176	NULL
)	NULL
.	NULL

Ten	NULL
microliters	NULL
of	NULL
the	NULL
RT-PCR	NULL
product	NULL
was	NULL
electrophoresed	NULL
in	NULL
agarose	NULL
gels	NULL
and	NULL
standard	NULL
Southern	NULL
blot	NULL
transfer	NULL
was	NULL
performed	NULL
.	NULL
'	NULL

''	NULL
Nitrocellulose	NULL
membranes	NULL
were	NULL
prehybrid-ized	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
65°C	NULL
in	NULL
5	NULL
mL	NULL
of	NULL
Rapid-Hyb	NULL
buffer	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Final	NULL
hybridization	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
525-bp	NULL
PCR-synthesized	NULL
NCAM	NULL
DNA	NULL
probe	NULL
spanning	NULL
the	NULL
region	NULL
initially	NULL
amplified	NULL
in	NULL
the	NULL
patient	NULL
samples	NULL
[	NULL
5	NULL
'	NULL
primer	NULL
:	NULL
NCAM	NULL
residues	NULL
1,667	NULL
through	NULL
1,686	NULL
(	NULL
5-GAGGCCACAGGTGGGGTGCC-3	NULL
'	NULL
)	NULL
;	NULL
3	NULL
``	NULL
primer	NULL
:	NULL
NCAM	NULL
residues	NULL
2,175	NULL
through	NULL
2,194	NULL
(	NULL
5-GGCTGTGGG-CTGGGCCGAGG-3	NULL
'	NULL
)	NULL
]	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
random	NULL
primed	NULL
(	NULL
Boehr-inger-Mannheim	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
and	NULL
the	NULL
membrane	NULL
was	NULL
hybridized	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
65°C	NULL
.	NULL

Stringency	NULL
washes	NULL
included	NULL
one	NULL
wash	NULL
of	NULL
15	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
0.1	NULL
x	NULL
SSC	NULL
,	NULL
0.1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
two	NULL
15-minute	NULL
washes	NULL
in	NULL
0.1	NULL
x	NULL
SSC	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
65°C	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

RT-PCR	NULL
assays	NULL
for	NULL
promyelocytic	NULL
(	NULL
PML	NULL
)	NULL
/retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
mRNA	NULL
transcripts	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
from	NULL
17/20	NULL
myeloid/NK	NULL
leukemia	NULL
cases	NULL
with	NULL
residual	NULL
cryopreserved	NULL
cells	NULL
(	NULL
all	NULL
cases	NULL
except	NULL
cases	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
from	NULL
3	NULL
AML-M3	NULL
cases	NULL
with	NULL
a	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
.	NULL
'	NULL

''	NULL
The	NULL
RT-PCR	NULL
amplification	NULL
method	NULL
used	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
Biondi	NULL
et	NULL
al	NULL
.	NULL
``	NULL

''	NULL
One	NULL
microgram	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
was	NULL
incubated	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
23°C	NULL
,	NULL
15	NULL
minutes	NULL
at	NULL
42°C	NULL
,	NULL
and	NULL
5	NULL
minutes	NULL
at	NULL
99°C	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
gL	NULL
containing	NULL
2	NULL
uL	NULL
of	NULL
10	NULL
x	NULL
buffer	NULL
(	NULL
100	NULL
mmol/L	NULL
TRIS	NULL
pH	NULL
8.3	NULL
,	NULL
0.5	NULL
mol/L	NULL
KCI	NULL
,	NULL
and	NULL
50	NULL
mmol/L	NULL
MgCI	NULL
;	NULL
)	NULL
,	NULL
2	NULL
LL	NULL
of	NULL
10	NULL
mmol/L	NULL
dNTPs	NULL
,	NULL
0.5	NULL
gL	NULL
of	NULL
100	NULL
pmol/	NULL
uL	NULL
random	NULL
hexamers	NULL
(	NULL
Boehringer-Mannheim	NULL
)	NULL
,	NULL
0.5	NULL
uL	NULL
of	NULL
RNAsin	NULL
(	NULL
20	NULL
U/O.5	NULL
uL	NULL
.	NULL
)	NULL

(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
2.0	NULL
LL	NULL
.	NULL

of	NULL
50	NULL
mmol/L	NULL
dithio-threitol	NULL
,	NULL
0.25	NULL
uL	NULL
of	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
(	NULL
MMLV	NULL
)	NULL
reverse	NULL
transcriptase	NULL
(	NULL
50	NULL
U/0.25	NULL
wL	NULL
)	NULL
(	NULL
GIBCO-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
7.75	NULL
gL	NULL
of	NULL
diethylprocarbonate-treated	NULL
H	NULL
,	NULL
O	NULL
.	NULL

Five	NULL
microliters	NULL
of	NULL
this	NULL
reaction	NULL
was	NULL
then	NULL
used	NULL
for	NULL
nested	NULL
RT-PCR	NULL
assays	NULL
using	NULL
primer	NULL
sequences	NULL
to	NULL
detect	NULL
PML/RARa	NULL
fusion	NULL
mRNAs	NULL
as	NULL
previously	NULL
described	NULL
:	NULL
M2R8	NULL
(	NULL
M2	NULL
derived	NULL
from	NULL
PML	NULL
exon	NULL
5	NULL
and	NULL
R8	NULL
from	NULL
RARa	NULL
exon	NULL
3	NULL
)	NULL
to	NULL
analyze	NULL
breakpoint	NULL
cluster	NULL
regions	NULL
(	NULL
ber	NULL
)	NULL
1	NULL
and	NULL
2	NULL
and	NULL
M4R8	NULL
(	NULL
M4	NULL
derived	NULL
from	NULL
PML	NULL
exon	NULL
3	NULL
)	NULL
to	NULL
analyze	NULL
ber	NULL
region	NULL
3	NULL
.	NULL

``	NULL
``	NULL
*	NULL
'	NULL
After	NULL
amplification	NULL
,	NULL
15	NULL
uL	NULL
of	NULL
the	NULL
PCR	NULL
reaction	NULL
was	NULL
fractionated	NULL
and	NULL
visualized	NULL
in	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gels	NULL
.	NULL

Amplification	NULL
of	NULL
32-microglobulin	NULL
mRNA	NULL
,	NULL
using	NULL
5	NULL
LL	NULL
of	NULL
the	NULL
cDNA	NULL
was	NULL
performed	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
RNA	NULL
integrity	NULL
and	NULL
PCR	NULL
reaction	NULL
fidelity	NULL
in	NULL
each	NULL
sample	NULL
,	NULL
using	NULL
an	NULL
annealing	NULL
temperature	NULL
of	NULL
55°C	NULL
.	NULL
``	NULL

RT-PCR	NULL
assays	NULL
for	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
zinc	NULL
finger	NULL
(	NULL
PLZF	NULL
)	NULL
/RARa	NULL
mRNA	NULL
transcripts	NULL
.	NULL

-	NULL
RT-PCR	NULL
was	NULL
performed	NULL
to	NULL
detect	NULL
the	NULL
PLZF/RARa-fusion	NULL
transcript	NULL
arising	NULL
from	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Total	NULL
RNA	NULL
(	NULL
4	NULL
pg	NULL
)	NULL
from	NULL
each	NULL
leukemic	NULL
sample	NULL
was	NULL
hybridized	NULL
to	NULL
a	NULL
primer	NULL
(	NULL
5-TGGATGCTGCGGCGGAAG-AAGCCCTTGCAG-3	NULL
'	NULL
)	NULL
complementary	NULL
to	NULL
the	NULL
B	NULL
region	NULL
of	NULL
the	NULL
RARa	NULL
gene	NULL
and	NULL
reverse	NULL
transcribed	NULL
by	NULL
incubation	NULL
with	NULL
200-U	NULL
SCOTT	NULL
ET	NULL
AL	NULL
MMLV	NULL
reverse	NULL
transcriptase	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
45	NULL
minutes	NULL
.	NULL

One	NULL
tenth	NULL
of	NULL
the	NULL
cDNA	NULL
product	NULL
was	NULL
then	NULL
amplified	NULL
by	NULL
PCR	NULL
using	NULL
Taq	NULL
polymerase	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
100-4L	NULL
volume	NULL
with	NULL
a	NULL
primer	NULL
complementary	NULL
to	NULL
the	NULL
B	NULL
region	NULL
of	NULL
the	NULL
RARa	NULL
(	NULL
5-GGGCACTATCTC-TTCAG-3	NULL
'	NULL
)	NULL
and	NULL
a	NULL
primer	NULL
complementary	NULL
to	NULL
the	NULL
B	NULL
region	NULL
of	NULL
PLZF	NULL
(	NULL
5-CTGTCTCCATGGACTTC-3	NULL
'	NULL
)	NULL
,	NULL
with	NULL
two	NULL
cycles	NULL
at	NULL
98°C	NULL
for	NULL
50	NULL
seconds	NULL
,	NULL
47°C	NULL
for	NULL
1.5	NULL
minutes	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
32	NULL
cycles	NULL
at	NULL
98°C	NULL
for	NULL
25	NULL
seconds	NULL
,	NULL
47°C	NULL
for	NULL
1.5	NULL
minutes	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
2	NULL
minutes	NULL
,	NULL
and	NULL
a	NULL
final	NULL
extension	NULL
for	NULL
12	NULL
minutes	NULL
at	NULL
72°C	NULL
.	NULL

Ten	NULL
microliters	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
were	NULL
electrophoretically	NULL
separated	NULL
through	NULL
a	NULL
1.4	NULL
%	NULL
agarose	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
prehybridized	NULL
,	NULL
and	NULL
hybridized	NULL
overnight	NULL
in	NULL
5	NULL
X	NULL
salt	NULL
sodium	NULL
phosphate	NULL
and	NULL
ethylendiamine	NULL
tetra-acetate	NULL
(	NULL
SSPE	NULL
)	NULL
,	NULL
5	NULL
x	NULL
Denhardt	NULL
's	NULL
,	NULL
1	NULL
mg/mL	NULL
salmon	NULL
sperm	NULL
DNA	NULL
at	NULL
63°C	NULL
with	NULL
a	NULL
radiolabeled	NULL
oligonucleotide	NULL
complementary	NULL
to	NULL
PLZF	NULL
(	NULL
5-TGGAGCAGCACAGGAAGCTGC-3	NULL
'	NULL
)	NULL
,	NULL
located	NULL
3	NULL
'	NULL
to	NULL
the	NULL
PLZF	NULL
amplification	NULL
primer	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
filters	NULL
were	NULL
autoradio-graphed	NULL
.	NULL

A	NULL
previously	NULL
identified	NULL
AML	NULL
patient	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
and	NULL
a	NULL
PLZF/RARa-fusion	NULL
product	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL
``	NULL

''	NULL
In	NULL
vitro	NULL
differentiation	NULL
studies	NULL
with	NULL
ATRA	NULL
.	NULL

-	NULL
Previously	NULL
eryopre-served	NULL
leukemic	NULL
blasts	NULL
from	NULL
four	NULL
patients	NULL
(	NULL
cases	NULL
11	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
and	NULL
16	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
from	NULL
two	NULL
AML-M3	NULL
patients	NULL
with	NULL
a	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
were	NULL
thawed	NULL
in	NULL
37°C	NULL
defrosting	NULL
medium	NULL
[	NULL
RPMI	NULL
1640	NULL
;	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
}	NULL
,	NULL
centrifuged	NULL
at	NULL
1,100	NULL
rpm	NULL
for	NULL
5	NULL
minutes	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
complete	NULL
culture	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
,	NULL
20	NULL
%	NULL
FCS	NULL
,	NULL
antibiotics	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
with	NULL
or	NULL
without	NULL
1	NULL
pmol/LATRA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
for	NULL
7	NULL
days	NULL
as	NULL
previously	NULL
de-scribed	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Aliquots	NULL
of	NULL
cells	NULL
removed	NULL
at	NULL
time	NULL
0	NULL
and	NULL
days	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
were	NULL
analyzed	NULL
by	NULL
cytologic	NULL
evaluation	NULL
and	NULL
differential	NULL
count	NULL
of	NULL
Wright	NULL
and	NULL
SBB-stained	NULL
cytospins	NULL
.	NULL

Maturation	NULL
was	NULL
defined	NULL
by	NULL
a	NULL
gain	NULL
in	NULL
cytoplasmic	NULL
volume	NULL
,	NULL
loss	NULL
of	NULL
cytoplasmic	NULL
granularity	NULL
after	NULL
the	NULL
promyelocytic	NULL
stage	NULL
,	NULL
and	NULL
nuclear	NULL
segmentation	NULL
.	NULL

In	NULL
vitro	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

-	NULL
The	NULL
cytotoxicity	NULL
of	NULL
previously	NULL
cryopreserved	NULL
leukemic	NULL
cell	NULL
suspensions	NULL
from	NULL
six	NULL
myeloid/NK	NULL
leukemia	NULL
cases	NULL
with	NULL
residual	NULL
cells	NULL
(	NULL
cases	NULL
3	NULL
,	NULL
10	NULL
[	NULL
a	NULL
posttreatment	NULL
relapse	NULL
specimen	NULL
was	NULL
analyzed	NULL
as	NULL
pretreatment	NULL
cells	NULL
were	NULL
not	NULL
available	NULL
]	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
and	NULL
19	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
was	NULL
tested	NULL
in	NULL
a	NULL
``	NULL
Chromium	NULL
(	NULL
Cr	NULL
)	NULL
release	NULL
functional	NULL
assay	NULL
.	NULL
``	NULL

An	NULL
NK	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
IMC-1	NULL
;	NULL
recently	NULL
developed	NULL
in	NULL
our	NULL
laboratory	NULL
)	NULL
and	NULL
an	NULL
AML-M3	NULL
sample	NULL
with	NULL
a	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL
``	NULL

''	NULL
Target	NULL
cells	NULL
included	NULL
the	NULL
NK	NULL
cell-susceptible	NULL
K562	NULL
(	NULL
human	NULL
erythroleukemia	NULL
)	NULL
line	NULL
.	NULL

Target	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
*'Cr	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
in	NULL
I	NULL
mL	NULL
of	NULL
bovine	NULL
calf	NULL
serum	NULL
(	NULL
BCS	NULL
)	NULL
(	NULL
50	NULL
wCi/l	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
at	NULL
37°C	NULL
in	NULL
air/	NULL
CO	NULL
,	NULL
(	NULL
19:1	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
complete	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
,	NULL
10	NULL
%	NULL
BCS	NULL
,	NULL
and	NULL
50	NULL
U	NULL
of	NULL
Penicillin/mL	NULL
.	NULL

,	NULL
50	NULL
ug/	NULL
mL	NULL
of	NULL
Streptomycin	NULL
,	NULL
and	NULL
50	NULL
pg/mL	NULL
Gentamicin	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Cryopreserved	NULL
leukemic	NULL
cells	NULL
(	NULL
effector	NULL
cells	NULL
)	NULL
were	NULL
defrosted	NULL
in	NULL
warm	NULL
defrosting	NULL
medium	NULL
,	NULL
centrifuged	NULL
at	NULL
1,100	NULL
rpm	NULL
for	NULL
5	NULL
minutes	NULL
,	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
complete	NULL
media	NULL
.	NULL

Effector	NULL
cells	NULL
were	NULL
added	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
cells/100	NULL
gL	NULL
for	NULL
a	NULL
50:1	NULL
ratio	NULL
)	NULL
to	NULL
the	NULL
wells	NULL
of	NULL
round-bottom	NULL
microtiter	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
and	NULL
were	NULL
diluted	NULL
at	NULL
ratios	NULL
of	NULL
25	NULL
:	NULL
1	NULL
(	NULL
2.5	NULL
x	NULL
105/100	NULL
L	NULL
)	NULL
,	NULL
12.5:1	NULL
(	NULL
1.25	NULL
x	NULL
10°/100	NULL
uL	NULL
)	NULL
,	NULL
6.25:1	NULL
(	NULL
6.25	NULL
x	NULL
10	NULL
%	NULL
/100	NULL
uL	NULL
)	NULL
,	NULL
and	NULL
3.12	NULL
:	NULL
1	NULL
(	NULL
3.12	NULL
x	NULL
10	NULL
%	NULL
/100	NULL
gL	NULL
)	NULL
.	NULL

For	NULL
assays	NULL
where	NULL
12:1	NULL
was	NULL
the	NULL
highest	NULL
effector	NULL
:	NULL
target	NULL
ratio	NULL
used	NULL
,	NULL
effectors	NULL
at	NULL
1.2	NULL
x	NULL
10°	NULL
cells/100	NULL
gL	NULL
were	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
and	NULL
the	NULL
appropriate	NULL
dilutions	NULL
were	NULL
made	NULL
.	NULL

Each	NULL
ratio	NULL
was	NULL
tested	NULL
in	NULL
triplicate	NULL
.	NULL

Targets	NULL
were	NULL
added	NULL
(	NULL
1	NULL
x	NULL
10°	NULL
cells/100	NULL
gL	NULL
)	NULL
to	NULL
each	NULL
well	NULL
,	NULL
and	NULL
the	NULL
plate	NULL
was	NULL
centrifuged	NULL
at	NULL
50g	NULL
for	NULL
3	NULL
minutes	NULL
and	NULL
incubated	NULL
for	NULL
4	NULL
hours	NULL
at	NULL
37°C	NULL
(	NULL
air/CO	NULL
;	NULL
,	NULL
19:1	NULL
)	NULL
.	NULL

Effector	NULL
and	NULL
target	NULL
cell	NULL
mixtures	NULL
were	NULL
assayed	NULL
before	NULL
incubation	NULL
with	NULL
recombinant	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
Chiron	NULL
Corp	NULL
,	NULL
Emoryville	NULL
,	NULL
CA	NULL
)	NULL
to	NULL
obtain	NULL
a	NULL
baseline	NULL
at	NULL
day	NULL
0	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
assayed	NULL
after	NULL
effector	NULL
cells	NULL
were	NULL
precultured	NULL
for	NULL
48	NULL
hours	NULL
with	NULL
1,000	NULL
U/mL	NULL
IL-2	NULL
and	NULL
complete	NULL
media	NULL
(	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
37°C	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
and	NULL
removal	NULL
of	NULL
the	NULL
IL-2	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
collected	NULL
using	NULL
a	NULL
harvesting	NULL
press	NULL
(	NULL
Skatron	NULL
,	NULL
Sterling	NULL
,	NULL
VA	NULL
)	NULL
and	NULL
counted	NULL
for	NULL
radioactivity	NULL
for	NULL
1	NULL
minute	NULL
in	NULL
a	NULL
gamma	NULL
counter	NULL
.	NULL

Specific	NULL
lysis	NULL
(	NULL
%	NULL
)	NULL
was	NULL
determined	NULL
as	NULL
follows	NULL
:	NULL
100	NULL
x	NULL
[	NULL
(	NULL
test	NULL
cpm	NULL
-	NULL
spontaneous	NULL
cpm	NULL
)	NULL
/	NULL
{	NULL
maximum	NULL
cpm	NULL
-	NULL
spontane-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
ous	NULL
cpm	NULL
)	NULL
]	NULL
,	NULL
with	NULL
maximum	NULL
release	NULL
determined	NULL
by	NULL
adding	NULL
100	NULL
LL	NULL
of	NULL
target	NULL
cells	NULL
to	NULL
wells	NULL
containing	NULL
100	NULL
gL	NULL
of	NULL
10	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL
``	NULL

''	NULL
Isolation	NULL
of	NULL
a	NULL
nonleukemic	NULL
CD33*	NULL
,	NULL
CD56	NULL
,	NULL
CD16	NULL
normal	NULL
counterpart	NULL
cell	NULL
.	NULL

NK	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
PB	NULL
buffy	NULL
coats	NULL
of	NULL
four	NULL
healthy	NULL
blood	NULL
donors	NULL
,	NULL
with	NULL
a	NULL
pooled	NULL
average	NULL
cell	NULL
count	NULL
of	NULL
4.7	NULL
%	NULL
10°/L	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
Ficoll-Hypaque	NULL
centrifugation	NULL
at	NULL
1,360	NULL
rom	NULL
(	NULL
400g	NULL
)	NULL
for	NULL
25	NULL
to	NULL
30	NULL
minutes	NULL
resuspended	NULL
in	NULL
2	NULL
mL	NULL
of	NULL
RPMI	NULL
,	NULL
and	NULL
layered	NULL
on	NULL
top	NULL
of	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
FCS	NULL
and	NULL
centrifuged	NULL
again	NULL
at	NULL
800	NULL
rpm	NULL
for	NULL
5	NULL
minutes	NULL
to	NULL
remove	NULL
platelets	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
complete	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
,	NULL
20	NULL
%	NULL
FCS	NULL
)	NULL
,	NULL
plated	NULL
on	NULL
plastic	NULL
petri	NULL
dishes	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
CO	NULL
;	NULL
incubator	NULL
to	NULL
remove	NULL
adherent	NULL
monocytes	NULL
.	NULL

The	NULL
nonadherent	NULL
cell	NULL
fraction	NULL
was	NULL
washed	NULL
and	NULL
T	NULL
lym-phocytes	NULL
were	NULL
removed	NULL
by	NULL
incubation	NULL
with	NULL
mouse	NULL
anti-CD3	NULL
anti-body	NULL
,	NULL
followed	NULL
by	NULL
rosetting	NULL
with	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
coated	NULL
with	NULL
rabbit-antimouse	NULL
IgG	NULL
.	NULL

A	NULL
second	NULL
Ficoll-Hypaque	NULL
centrifugation	NULL
was	NULL
performed	NULL
to	NULL
remove	NULL
rosetted	NULL
T	NULL
cells	NULL
and	NULL
the	NULL
nonrosetted	NULL
cell	NULL
layer	NULL
was	NULL
harvested	NULL
.	NULL

This	NULL
NK	NULL
cell-enriched	NULL
population	NULL
was	NULL
then	NULL
directly	NULL
labeled	NULL
for	NULL
three-color	NULL
flow	NULL
cytometric	NULL
analysis	NULL
;	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
purified	NULL
CD56	NULL
antibody	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
then	NULL
labeled	NULL
with	NULL
biotinylated	NULL
goat-antimouse	NULL
IgG	NULL
F	NULL
(	NULL
ab	NULL
)	NULL
.	NULL

After	NULL
a	NULL
blocking	NULL
step	NULL
with	NULL
goat	NULL
serum	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
FITC-conjugated	NULL
CD33	NULL
(	NULL
Coulter	NULL
)	NULL
and	NULL
PE-conjugated	NULL
CD16	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
Hanks	NULL
'	NULL
Balanced	NULL
Salt	NULL
Solution	NULL
(	NULL
HBSS	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
streptavidin	NULL
PE-conjugated	NULL
Texas	NULL
Red	NULL
(	NULL
RED613	NULL
)	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
then	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
HBSS	NULL
.	NULL

Cells	NULL
were	NULL
initially	NULL
sorted	NULL
using	NULL
forward-angle	NULL
light-scatter	NULL
and	NULL
side-scatter	NULL
parameters	NULL
on	NULL
a	NULL
Coulter	NULL
753	NULL
Cell	NULL
Sorter	NULL
to	NULL
select	NULL
for	NULL
a	NULL
small	NULL
to	NULL
medium-sized	NULL
,	NULL
nongranular	NULL
population	NULL
;	NULL
cells	NULL
stained	NULL
with	NULL
mouse	NULL
isotype	NULL
control	NULL
antibodies	NULL
were	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
to	NULL
establish	NULL
gating	NULL
param-eters	NULL
.	NULL

Additional	NULL
gating	NULL
was	NULL
performed	NULL
on	NULL
CDS56*	NULL
and	NULL
CD33*	NULL
cells	NULL
to	NULL
obtain	NULL
CD16*	NULL
and	NULL
CD16~	NULL
populations	NULL
for	NULL
cytospin	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
evaluation	NULL
.	NULL

Clinical	NULL
and	NULL
outcome	NULL
data	NULL
.	NULL

-	NULL
Clinical	NULL
data	NULL
for	NULL
patients	NULL
registered	NULL
on	NULL
treatment	NULL
studies	NULL
SWOG	NULL
8600	NULL
or	NULL
9031	NULL
were	NULL
obtained	NULL
from	NULL
SWOG	NULL
central	NULL
data	NULL
base	NULL
and	NULL
were	NULL
subjected	NULL
to	NULL
standard	NULL
SWOG	NULL
247	NULL
procedures	NULL
for	NULL
reporting	NULL
and	NULL
quality	NULL
control	NULL
.	NULL

Seventeen	NULL
of	NULL
these	NULL
patients	NULL
were	NULL
registered	NULL
on	NULL
SWOG	NULL
AML	NULL
frontline	NULL
studies	NULL
(	NULL
11	NULL
on	NULL
SWOG	NULL
8600	NULL
,	NULL
3	NULL
on	NULL
SWOG	NULL
9031	NULL
,	NULL
and	NULL
2	NULL
on	NULL
SWOG	NULL
9034	NULL
)	NULL
;	NULL
three	NULL
patients	NULL
were	NULL
not	NULL
ultimately	NULL
registered	NULL
on	NULL
any	NULL
SWOG	NULL
treatment	NULL
study	NULL
(	NULL
cases	NULL
12	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Data	NULL
for	NULL
patients	NULL
registered	NULL
on	NULL
study	NULL
SWOG	NULL
9034	NULL
,	NULL
an	NULL
intergroup	NULL
study	NULL
coordinated	NULL
by	NULL
Eastern	NULL
Cooperative	NULL
Oncology	NULL
Group	NULL
(	NULL
ECOG	NULL
)	NULL
,	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
ECOG	NULL
central	NULL
data	NULL
base	NULL
.	NULL

Data	NULL
for	NULL
patients	NULL
who	NULL
were	NULL
not	NULL
registered	NULL
on	NULL
SWOG	NULL
treatment	NULL
studies	NULL
(	NULL
cases	NULL
12	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
hematologist-oncologist	NULL
responsible	NULL
for	NULL
the	NULL
patient	NULL
's	NULL
care	NULL
.	NULL

Overall	NULL
survival	NULL
was	NULL
measured	NULL
from	NULL
the	NULL
day	NULL
of	NULL
registration	NULL
on	NULL
SWOG	NULL
treatment	NULL
study	NULL
(	NULL
or	NULL
the	NULL
start	NULL
date	NULL
of	NULL
induction	NULL
therapy	NULL
for	NULL
non-SWOG	NULL
patients	NULL
)	NULL
until	NULL
death	NULL
from	NULL
any	NULL
cause	NULL
.	NULL

Relapse-free	NULL
survival	NULL
(	NULL
RFS	NULL
)	NULL
was	NULL
measured	NULL
from	NULL
the	NULL
onset	NULL
of	NULL
complete	NULL
response	NULL
until	NULL
relapse	NULL
or	NULL
death	NULL
from	NULL
any	NULL
cause	NULL
,	NULL
with	NULL
observation	NULL
censored	NULL
at	NULL
the	NULL
date	NULL
of	NULL
last	NULL
contact	NULL
for	NULL
living	NULL
patients	NULL
with	NULL
no	NULL
report	NULL
of	NULL
relapse	NULL
.	NULL

Median	NULL
durations	NULL
of	NULL
survival	NULL
and	NULL
RFS	NULL
were	NULL
obtained	NULL
from	NULL
distributions	NULL
estimated	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Kaplan	NULL
and	NULL
Meier	NULL
.	NULL
``	NULL

The	NULL
BM	NULL
differential	NULL
data	NULL
listed	NULL
in	NULL
Table	NULL
2	NULL
is	NULL
based	NULL
on	NULL
the	NULL
local	NULL
institutional	NULL
pathology	NULL
.	NULL

RESULTS	NULL
Flow	NULL
cytometric	NULL
immunophenotypic	NULL
studies	NULL
.	NULL

|	NULL
Pretreatment	NULL
BM	NULL
and	NULL
PB	NULL
specimens	NULL
from	NULL
patients	NULL
who	NULL
were	NULL
candidates	NULL
for	NULL
frontline	NULL
AML	NULL
treatment	NULL
studies	NULL
SWOG	NULL
8600	NULL
,	NULL
9031	NULL
,	NULL
and	NULL
9034	NULL
were	NULL
reviewed	NULL
for	NULL
possible	NULL
inclusion	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Specimens	NULL
from	NULL
350	NULL
consecutive	NULL
patients	NULL
were	NULL
examined	NULL
and	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
hematopoietic	NULL
cell	NULL
surface	NULL
antigen	NULL
expression	NULL
showed	NULL
20	NULL
cases	NULL
(	NULL
6	NULL
%	NULL
)	NULL
with	NULL
a	NULL
unique	NULL
immunophenotypic	NULL
profile	NULL
.	NULL

These	NULL
20	NULL
cases	NULL
were	NULL
characterized	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
by	NULL
the	NULL
coexpression	NULL
of	NULL
various	NULL
myeloid	NULL
(	NULL
CD33	NULL
,	NULL
CD13	NULL
,	NULL
CD15	NULL
)	NULL
and	NULL
NK	NULL
cell-associated	NULL
(	NULL
CD56	NULL
)	NULL
surface	NULL
antigens	NULL
;	NULL
the	NULL
detailed	NULL
immunophenotypic	NULL
profile	NULL
in	NULL
each	NULL
case	NULL
is	NULL
provided	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Like	NULL
AML	NULL
cases	NULL
of	NULL
the	NULL
FAB	NULL
M3	NULL
subtype	NULL
,	NULL
all	NULL
cases	NULL
consis-	NULL
Table	NULL
2	NULL
.	NULL

Myeloid/NK	NULL
Precursor	NULL
Cell	NULL
Acute	NULL
Leukemia	NULL
Cases	NULL
:	NULL
Pretreatment	NULL
Clinical	NULL
Characteristics	NULL
and	NULL
Therapeutic	NULL
Response	NULL
WBC	NULL
BM	NULL
BM	NULL
Extramedullary	NULL
Bleeding	NULL
Response	NULL
to	NULL
Survival	NULL
Case	NULL
No	NULL
.	NULL

Age/Sex	NULL
(	NULL
x10	NULL
)	NULL
(	NULL
%	NULL
blasts	NULL
)	NULL
(	NULL
%	NULL
promyelocytes	NULL
)	NULL
Disease	NULL
Diathesis	NULL
Induction	NULL
TX	NULL
(	NULL
d	NULL
)	NULL
1	NULL
52/M	NULL
4.7	NULL
71	NULL
4	NULL
None	NULL
,	NULL
CNS	NULL
Unk	NULL
None	NULL
CR	NULL
282	NULL
2	NULL
68/M	NULL
33.8	NULL
98	NULL
<	NULL
1	NULL
None	NULL
None	NULL
ED	NULL
23	NULL
3	NULL
35/F	NULL
155.1	NULL
98	NULL
0	NULL
None	NULL
None	NULL
CR	NULL
486+	NULL
4	NULL
43/F	NULL
6.2	NULL
92	NULL
0	NULL
None	NULL
,	NULL
CNS	NULL
Unk	NULL
None	NULL
CR	NULL
754+	NULL
5	NULL
18/M	NULL
16.2	NULL
>	NULL
95	NULL
0	NULL
None	NULL
None	NULL
CR	NULL
1,309	NULL
6	NULL
62/F	NULL
218.0	NULL
93	NULL
0	NULL
None	NULL
None	NULL
CR	NULL
133	NULL
7	NULL
43/M	NULL
78.7	NULL
90	NULL
0	NULL
H	NULL
,	NULL
S	NULL
Mild	NULL
CR	NULL
1,620+	NULL
8	NULL
64/M	NULL
53.9	NULL
96	NULL
1	NULL
None	NULL
None	NULL
NASS	NULL
19	NULL
9	NULL
72/F	NULL
88.6	NULL
91	NULL
<	NULL
1	NULL
None	NULL
Mild	NULL
B	NULL
NR	NULL
61+	NULL
10	NULL
41/M	NULL
1.0	NULL
87	NULL
1	NULL
None	NULL
Mild	NULL
NR	NULL
68	NULL
11	NULL
28/M	NULL
86.1	NULL
ND	NULL
ND	NULL
H	NULL
,	NULL
Ing	NULL
None	NULL
CR	NULL
1,798+	NULL
12	NULL
66/M	NULL
13.9	NULL
88	NULL
7	NULL
None	NULL
Mild	NULL
CR	NULL
1,085+	NULL
13	NULL
44/F	NULL
91.7	NULL
99	NULL
Ax	NULL
,	NULL
Ing	NULL
None	NULL
NASS	NULL
1,990+	NULL
14	NULL
48/M	NULL
328.0	NULL
>	NULL
95	NULL
0	NULL
None	NULL
None	NULL
NR	NULL
45	NULL
15	NULL
48/F	NULL
212.7	NULL
99	NULL
0	NULL
None	NULL
Mild	NULL
CR	NULL
907	NULL
16	NULL
35/F	NULL
45.2	NULL
47	NULL
10	NULL
None	NULL
Moderate	NULL
NR	NULL
350	NULL
17	NULL
48/F	NULL
71.3	NULL
98	NULL
0	NULL
ANOS	NULL
Mild	NULL
CR	NULL
28+	NULL
18	NULL
60/M	NULL
98.2	NULL
82	NULL
Unk	NULL
None	NULL
Mild	NULL
CR	NULL
146+	NULL
19	NULL
48/F	NULL
89.0	NULL
79	NULL
0	NULL
Cx	NULL
Mild	NULL
ED	NULL
5	NULL
20	NULL
57/F	NULL
8.2	NULL
90	NULL
Unk	NULL
None	NULL
None	NULL
NR	NULL
81	NULL
Abbreviations	NULL
:	NULL
Extramedullary	NULL
disease	NULL
:	NULL
Ax	NULL
,	NULL
axillary	NULL
lymphadenopathy	NULL
;	NULL
Cx	NULL
,	NULL
cervical	NULL
lymphadenopathy	NULL
;	NULL
Ing	NULL
,	NULL
inguinal	NULL
lymphadenopathy	NULL
;	NULL
ANOS	NULL
,	NULL
adenopathy	NULL
site	NULL
unspecified	NULL
;	NULL
S	NULL
,	NULL
splenomegaly	NULL
;	NULL
H	NULL
,	NULL
hepatomegaly	NULL
;	NULL
CNS	NULL
,	NULL
central	NULL
nervous	NULL
system	NULL
.	NULL

Response	NULL
to	NULL
induction	NULL
therapy	NULL
(	NULL
TX	NULL
)	NULL
:	NULL
CR	NULL
,	NULL
complete	NULL
remission	NULL
;	NULL
ED	NULL
,	NULL
early	NULL
death	NULL
;	NULL
NASS	NULL
,	NULL
not	NULL
adequately	NULL
assessed	NULL
;	NULL
NR	NULL
,	NULL
no	NULL
response	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
done	NULL
;	NULL
Unk	NULL
,	NULL
unknown	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

248	NULL
r	NULL
50	NULL
%	NULL
Log	NULL
T	NULL
%	NULL
a	NULL
F	NULL
s	NULL
nek	NULL
Ls	NULL
a	NULL
A	NULL
9	NULL
B	NULL
H	NULL
an	NULL
3	NULL
]	NULL
~	NULL
in	NULL
|	NULL
10	NULL
s	NULL
o	NULL
Cex	NULL
o	NULL
09	NULL
as	NULL
U	NULL
¢	NULL
h	NULL
gt	NULL
“	NULL
«	NULL
-	NULL
&	NULL
|	NULL
]	NULL
7¢	NULL
*	NULL
CD56	NULL
TR	NULL
]	NULL
;	NULL
]	NULL
HLA-DR	NULL
_TR	NULL
7	NULL
T0	NULL
162	NULL
19	NULL
ian	NULL
7160	NULL
``	NULL
6	NULL
162	NULL
16	NULL
it	NULL
x	NULL
;	NULL
Log	NULL
%	NULL
M	NULL
’	NULL
G	NULL
``	NULL
IH	NULL
C	NULL
10	NULL
D	NULL
Pa	NULL
H	NULL
[	NULL
»	NULL
a	NULL
|	NULL
a	NULL
Rim	NULL
kor	NULL
A	NULL
w	NULL
0	NULL
«	NULL
A	NULL
A	NULL
*	NULL
$	NULL
0	NULL
E	NULL
7	NULL
at	NULL
{	NULL
~~	NULL
cD16_FITC	NULL
CD56__TR	NULL
7	NULL
10+	NULL
102	NULL
10	NULL
16	NULL
162	NULL
10	NULL
18	NULL
``	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
Two-color	NULL
contour	NULL
plots	NULL
derived	NULL
from	NULL
three-color	NULL
flow	NULL
cyto-	NULL
metric	NULL
analysis	NULL
of	NULL
gated	NULL
blasts	NULL
from	NULL
a	NULL
representative	NULL
case	NULL
of	NULL
myeloid/	NULL
NK	NULL
acute	NULL
leukemia	NULL
with	NULL
PE	NULL
,	NULL
FITC	NULL
,	NULL
and	NULL
Texas	NULL
Red	NULL
(	NULL
TR	NULL
)	NULL
-conjugated	NULL
antibodies	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Coexpression	NULL
of	NULL
CD33-PE	NULL
(	NULL
Y-axis	NULL
)	NULL
and	NULL
CD56-TR	NULL
(	NULL
X-axis	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Expression	NULL
of	NULL
CD33-PE	NULL
(	NULL
Y-axis	NULL
)	NULL
and	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
HLA-DR-TR	NULL
(	NULL
X-axis	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Expression	NULL
of	NULL
CD33-PE	NULL
(	NULL
Y-axis	NULL
)	NULL
and	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
CD16-FITC	NULL
(	NULL
X-axis	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Expression	NULL
of	NULL
CD56-TR	NULL
(	NULL
X-axis	NULL
)	NULL
and	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
CD16-FITC	NULL
(	NULL
Y-axis	NULL
)	NULL
.	NULL

tently	NULL
lacked	NULL
expression	NULL
of	NULL
HLA-DR	NULL
,	NULL
an	NULL
antigen	NULL
that	NULL
is	NULL
preferentially	NULL
expressed	NULL
by	NULL
myeloblasts	NULL
and	NULL
lost	NULL
during	NULL
maturation	NULL
to	NULL
the	NULL
promyelocytic	NULL
stage	NULL
.	NULL
``	NULL

''	NULL
Although	NULL
two	NULL
cases	NULL
were	NULL
positive	NULL
for	NULL
CD4	NULL
,	NULL
this	NULL
antigen	NULL
is	NULL
not	NULL
T-cell	NULL
lineage	NULL
specific	NULL
and	NULL
may	NULL
frequently	NULL
be	NULL
expressed	NULL
on	NULL
AML	NULL
blasts	NULL
and	NULL
on	NULL
a	NULL
subset	NULL
of	NULL
PB	NULL
monocytes	NULL
.	NULL

``	NULL
*	NULL
The	NULL
absence	NULL
of	NULL
T-cell	NULL
lineage	NULL
commitment	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
T-cell	NULL
lineage-associated	NULL
antigens	NULL
CD2	NULL
,	NULL
CD3	NULL
,	NULL
and	NULL
CD8	NULL
and	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
clonal	NULL
rearrangement	NULL
of	NULL
genes	NULL
encoding	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
#	NULL
,	NULL
y	NULL
,	NULL
81	NULL
,	NULL
and	NULL
82	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
cases	NULL
were	NULL
characterized	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
myeloid-associated	NULL
antigens	NULL
CD33	NULL
,	NULL
CD13	NULL
,	NULL
and/or	NULL
CD15	NULL
;	NULL
the	NULL
hematopoietic	NULL
stem	NULL
and	NULL
progenitor	NULL
cell	NULL
antigen	NULL
CD34	NULL
was	NULL
expressed	NULL
at	NULL
low	NULL
antigen	NULL
density	NULL
in	NULL
6/20	NULL
cases	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

All	NULL
cases	NULL
expressed	NULL
CD56	NULL
(	NULL
a	NULL
variantly	NULL
spliced	NULL
form	NULL
of	NULL
the	NULL
NCAM	NULL
)	NULL
**	NULL
at	NULL
high	NULL
antigen	NULL
density	NULL
and	NULL
did	NULL
not	NULL
express	NULL
CD16	NULL
(	NULL
the	NULL
immunoglobulin	NULL
Fey	NULL
receptor	NULL
)	NULL
.	NULL

The	NULL
CD1	NULL
1a	NULL
adhesion	NULL
molecule	NULL
required	NULL
for	NULL
NK	NULL
cell-mediated	NULL
cytotoxic-ity	NULL
,	NULL
``	NULL
``	NULL
5°	NULL
was	NULL
also	NULL
expressed	NULL
at	NULL
high	NULL
antigen	NULL
density	NULL
in	NULL
all	NULL
cases	NULL
in	NULL
which	NULL
it	NULL
was	NULL
assessed	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
Cases	NULL
1	NULL
through	NULL
10	NULL
)	NULL
.	NULL

Coexpression	NULL
of	NULL
CDS6	NULL
and	NULL
myeloid-associated	NULL
antigens	NULL
(	NULL
CD33	NULL
,	NULL
CD13	NULL
,	NULL
and	NULL
CD15	NULL
)	NULL
was	NULL
confirmed	NULL
in	NULL
each	NULL
case	NULL
by	NULL
two-	NULL
and	NULL
three-color	NULL
flow	NULL
cytometric	NULL
studies	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

RT-PCR	NULL
and	NULL
oligonucleotide	NULL
probe	NULL
hybridization	NULL
assays	NULL
for	NULL
CD56	NULL
(	NULL
NCAM	NULL
)	NULL
.	NULL

_	NULL
To	NULL
confirm	NULL
that	NULL
CD56	NULL
,	NULL
and	NULL
not	NULL
a	NULL
cross-reactive	NULL
epitope	NULL
,	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
,	NULL
RT-PCR	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
detect	NULL
CD56	NULL
(	NULL
NCAM	NULL
)	NULL
mRNA	NULL
transcripts	NULL
in	NULL
leukemic	NULL
blasts	NULL
.	NULL

A	NULL
major	NULL
493-bp	NULL
CD56	NULL
(	NULL
NCAM	NULL
)	NULL
PCR	NULL
product	NULL
was	NULL
identified	NULL
in	NULL
each	NULL
of	NULL
two	NULL
cases	NULL
tested	NULL
(	NULL
Cases	NULL
8	NULL
and	NULL
15	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
(	NULL
Fig	NULL
SCOTT	NULL
ET	NULL
AL	NULL
2A	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
also	NULL
included	NULL
the	NULL
CD56*	NULL
myeloma	NULL
cell	NULL
line	NULL
$	NULL
226/Dox40	NULL
used	NULL
as	NULL
a	NULL
high-level	NULL
positive	NULL
control	NULL
and	NULL
an	NULL
AML	NULL
case	NULL
with	NULL
very	NULL
low	NULL
CD56	NULL
expression	NULL
(	NULL
1	NULL
%	NULL
by	NULL
flow	NULL
cytometry	NULL
)	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
this	NULL
493-bp	NULL
product	NULL
has	NULL
been	NULL
previously	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequenc-ing	NULL
.	NULL

'®	NULL
Hybridization	NULL
of	NULL
the	NULL
RT-PCR	NULL
products	NULL
with	NULL
an	NULL
NCAM	NULL
DNA	NULL
probe	NULL
confirmed	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
RT-PCR	NULL
products	NULL
(	NULL
Fig	NULL
2B	NULL
)	NULL
.	NULL

Review	NULL
of	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
.	NULL

The	NULL
referring	NULL
institutional	NULL
FAB	NULL
diagnoses	NULL
were	NULL
as	NULL
follows	NULL
for	NULL
the	NULL
20	NULL
cases	NULL
:	NULL
1	NULL
MO/L2	NULL
,	NULL
10	NULL
M1	NULL
,	NULL
5	NULL
M2	NULL
,	NULL
2	NULL
M3	NULL
,	NULL
and	NULL
2	NULL
M4	NULL
.	NULL

Upon	NULL
rereview	NULL
of	NULL
BM	NULL
aspirates	NULL
and	NULL
PB	NULL
smears	NULL
in	NULL
each	NULL
case	NULL
by	NULL
the	NULL
SWOG	NULL
Leukemia	NULL
Review	NULL
Panel	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
cases	NULL
(	NULL
13/20	NULL
)	NULL
were	NULL
noted	NULL
to	NULL
have	NULL
distinct	NULL
,	NULL
yet	NULL
similar	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
(	NULL
which	NULL
we	NULL
have	NULL
chosen	NULL
to	NULL
designate	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
features	NULL
included	NULL
strikingly	NULL
invaginated	NULL
nuclear	NULL
membranes	NULL
,	NULL
scant	NULL
to	NULL
moderate	NULL
cytoplasm	NULL
with	NULL
fine	NULL
to	NULL
moderately	NULL
coarse	NULL
azurophilic	NULL
granules	NULL
,	NULL
and	NULL
weak	NULL
to	NULL
moderate	NULL
finely	NULL
granular	NULL
SBB	NULL
and/or	NULL
MPO	NULL
cytochemical	NULL
reactivity	NULL
(	NULL
Fig	NULL
3	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
features	NULL
were	NULL
highly	NULL
reminiscent	NULL
of	NULL
AML-M3	NULL
,	NULL
particularly	NULL
the	NULL
microgranular	NULL
variant	NULL
(	NULL
AML-M3v	NULL
)	NULL
(	NULL
Fig	NULL
3B	NULL
)	NULL
,	NULL
distinct	NULL
differences	NULL
were	NULL
apparent	NULL
.	NULL

Whereas	NULL
occasional	NULL
myeloid/NK	NULL
blasts	NULL
had	NULL
conspicuous	NULL
cytoplasmic	NULL
granules	NULL
,	NULL
they	NULL
were	NULL
not	NULL
as	NULL
prominent	NULL
as	NULL
typical	NULL
AML-M3	NULL
blasts	NULL
;	NULL
moreover	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
weak	NULL
or	NULL
moderate	NULL
finely	NULL
granular	NULL
SBB	NULL
or	NULL
MPO	NULL
positivity	NULL
was	NULL
distinct	NULL
from	NULL
the	NULL
intense	NULL
and	NULL
dense	NULL
SBB	NULL
and	NULL
MPO	NULL
staining	NULL
of	NULL
AML-M3	NULL
and	NULL
MB3v	NULL
(	NULL
Fig	NULL
3D	NULL
)	NULL
.	NULL

Rare	NULL
myeloid/NK	NULL
blasts	NULL
contained	NULL
Auer	NULL
rods	NULL
;	NULL
bundles	NULL
of	NULL
Auer	NULL
rods	NULL
(	NULL
faggot	NULL
cells	NULL
)	NULL
characteristic	NULL
of	NULL
FAB	NULL
M3	NULL
were	NULL
not	NULL
present	NULL
.	NULL

All	NULL
cases	NULL
were	NULL
characterized	NULL
by	NULL
a	NULL
high	NULL
marrow-blast	NULL
percentage	NULL
(	NULL
median	NULL
blast	NULL
cell	NULL
percentage	NULL
,	NULL
92	NULL
%	NULL
;	NULL
range	NULL
of	NULL
47	NULL
%	NULL
to	NULL
99	NULL
%	NULL
)	NULL
;	NULL
however	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
cases	NULL
of	NULL
AML-M3	NULL
,	NULL
increased	NULL
numbers	NULL
of	NULL
marrow	NULL
promyelocytes	NULL
were	NULL
not	NULL
seen	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Increased	NULL
numbers	NULL
of	NULL
cells	NULL
with	NULL
large	NULL
granular	NULL
S	NULL
1	NULL
2	NULL
3	NULL
4	NULL
S	NULL
12	NULL
3	NULL
4	NULL
B	NULL
500bp	NULL
»	NULL
wae	NULL
_	NULL
-	NULL
<	NULL
493bp	NULL
Fig	NULL
2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Ethidium-stained	NULL
gel	NULL
of	NULL
NCAM	NULL
RT-PCR	NULL
products	NULL
.	NULL

DNA	NULL
size	NULL
markers	NULL
(	NULL
in	NULL
bp	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
lane	NULL
S.	NULL
A	NULL
major	NULL
493-bp	NULL
NCAM	NULL
RT-PCR	NULL
product	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
CD56®	NULL
8226/DOX40	NULL
cell	NULL
line	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
while	NULL
an	NULL
AML	NULL
sample	NULL
lacking	NULL
CD56	NULL
(	NULL
<	NULL
1	NULL
%	NULL
by	NULL
flow	NULL
cytometry	NULL
)	NULL
essentially	NULL
lacks	NULL
this	NULL
product	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Two	NULL
CD56®	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemia	NULL
cases	NULL
in	NULL
lane	NULL
2	NULL
(	NULL
Case	NULL
8	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
lane	NULL
3	NULL
(	NULL
Case	NULL
15	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
show	NULL
the	NULL
major	NULL
493-bp	NULL
NCAM	NULL
RT-PCR	NULL
product	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Autoradiograph	NULL
of	NULL
the	NULL
gel	NULL
in	NULL
A	NULL
hybridized	NULL
with	NULL
an	NULL
NCAM-specific	NULL
DNA	NULL
probe	NULL
.	NULL

Hybridization	NULL
confirms	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
NCAM	NULL
RT-PCR	NULL
products	NULL
;	NULL
lanes	NULL
as	NULL
identified	NULL
in	NULL
Fig	NULL
2A	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
of	NULL
myeloid/NK	NULL
acute	NULL
leukemias	NULL
in	NULL
comparison	NULL
to	NULL
AML-M3v	NULL
blasts	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Wright-stained	NULL
myeloid/NK	NULL
leukemic	NULL
blasts	NULL
;	NULL
note	NULL
deeply	NULL
invaginated	NULL
nuclear	NULL
membranes	NULL
and	NULL
fine	NULL
azurophilic	NULL
granularity	NULL
of	NULL
cytoplasm	NULL
.	NULL

Original	NULL
magnification	NULL
x	NULL
1,000	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Wright-stained	NULL
AML-M3v	NULL
;	NULL
note	NULL
similarities	NULL
to	NULL
A	NULL
.	NULL

Original	NULL
magnification	NULL
x	NULL
1,000	NULL
.	NULL

(	NULL
C	NULL
)	NULL
SBB-stained	NULL
myeloid/NK	NULL
leukemic	NULL
blasts	NULL
;	NULL
note	NULL
finely	NULL
granular	NULL
staining	NULL
pattern	NULL
.	NULL

(	NULL
D	NULL
)	NULL
SBB-stained	NULL
AML-M3v	NULL
blasts	NULL
;	NULL
note	NULL
intense	NULL
and	NULL
dense	NULL
staining	NULL
pattern	NULL
.	NULL

249	NULL
Fig	NULL
6	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
nonleukemic	NULL
PB	NULL
counterpart	NULL
cell	NULL
.	NULL

(	NULL
A	NULL
)	NULL
After	NULL
a	NULL
three-step	NULL
isolation	NULL
process	NULL
to	NULL
enrich	NULL
for	NULL
NK	NULL
cells	NULL
from	NULL
buffy	NULL
coats	NULL
,	NULL
a	NULL
population	NULL
of	NULL
small	NULL
to	NULL
intermediate-sized	NULL
-	NULL
cells	NULL
with	NULL
low	NULL
side	NULL
scatter	NULL
was	NULL
selected	NULL
for	NULL
flow	NULL
cytometric	NULL
sorting	NULL
(	NULL
the	NULL
population	NULL
selected	NULL
for	NULL
sorting	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
electronic	NULL
gates	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
From	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
obtained	NULL
in	NULL
(	NULL
A	NULL
)	NULL
,	NULL
a	NULL
sub-population	NULL
of	NULL
cells	NULL
with	NULL
strong	NULL
coexpression	NULL
of	NULL
CD33	NULL
and	NULL
CD56	NULL
was	NULL
obtained	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Next	NULL
,	NULL
the	NULL
CD33*	NULL
,	NULL
CD56*	NULL
copositive	NULL
cells	NULL
shown	NULL
in	NULL
(	NULL
B	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
CD16	NULL
.	NULL

A	NULL
population	NULL
of	NULL
CD33*	NULL
,	NULL
CD56®	NULL
,	NULL
CD16~	NULL
cells	NULL
were	NULL
then	NULL
selected	NULL
in	NULL
the	NULL
final	NULL
sort	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Morphologic	NULL
features	NULL
of	NULL
the	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
sorted	NULL
cells	NULL
;	NULL
these	NULL
cells	NULL
display	NULL
large	NULL
granular	NULL
lymphocyte	NULL
morphology	NULL
with	NULL
irregular	NULL
or	NULL
indented	NULL
nuclei	NULL
with	NULL
coarsely	NULL
clumped	NULL
chromatin	NULL
and	NULL
a	NULL
moderate	NULL
amount	NULL
of	NULL
cytoplasm	NULL
with	NULL
small	NULL
azurophilic	NULL
granules	NULL
.	NULL

Original	NULL
magnification	NULL
x	NULL
1,000	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

250	NULL
lymphocyte	NULL
(	NULL
LGL	NULL
)	NULL
morphology	NULL
associated	NULL
with	NULL
the	NULL
NK	NULL
cell	NULL
lineage	NULL
were	NULL
seen	NULL
in	NULL
the	NULL
BM	NULL
aspirates	NULL
and	NULL
PB	NULL
smears	NULL
of	NULL
some	NULL
cases	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
whether	NULL
these	NULL
cells	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
leukemic	NULL
clone	NULL
or	NULL
represented	NULL
residual	NULL
normal	NULL
NK	NULL
cells	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Whereas	NULL
seven	NULL
of	NULL
the	NULL
remaining	NULL
cases	NULL
(	NULL
cases	NULL
1	NULL
,	NULL
3	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
12	NULL
,	NULL
16	NULL
,	NULL
and	NULL
19	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
had	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
similarities	NULL
to	NULL
cases	NULL
designated	NULL
as	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
,	NULL
the	NULL
overall	NULL
features	NULL
were	NULL
equally	NULL
consistent	NULL
with	NULL
an	NULL
MI	NULL
,	NULL
M2	NULL
,	NULL
or	NULL
M7	NULL
designation	NULL
in	NULL
the	NULL
FAB	NULL
classification	NULL
system	NULL
and	NULL
these	NULL
cases	NULL
are	NULL
designated	NULL
in	NULL
this	NULL
fashion	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Pretreatment	NULL
clinical	NULL
characteristics	NULL
and	NULL
therapeutic	NULL
re-sponse	NULL
.	NULL

-	NULL
Detailed	NULL
pretreatment	NULL
clinical	NULL
characteristics	NULL
and	NULL
therapeutic	NULL
responses	NULL
are	NULL
provided	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Median	NULL
age	NULL
at	NULL
time	NULL
of	NULL
treatment	NULL
was	NULL
48	NULL
years	NULL
(	NULL
range	NULL
,	NULL
18	NULL
to	NULL
72	NULL
years	NULL
)	NULL
with	NULL
an	NULL
equal	NULL
sex	NULL
distribution	NULL
(	NULL
10	NULL
women	NULL
,	NULL
10	NULL
men	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
patients	NULL
presented	NULL
with	NULL
high	NULL
white	NULL
blood	NULL
cell	NULL
counts	NULL
at	NULL
presentation	NULL
with	NULL
a	NULL
median	NULL
of	NULL
75.0	NULL
x	NULL
10°/L	NULL
(	NULL
range	NULL
of	NULL
1.0	NULL
x	NULL
10°/L	NULL
to	NULL
328.0	NULL
x	NULL
10°/L	NULL
;	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
median	NULL
PB	NULL
lymphocyte	NULL
count	NULL
was	NULL
3,800/uL	NULL
(	NULL
range	NULL
,	NULL
400	NULL
to	NULL
15,300/uL	NULL
)	NULL
;	NULL
9/18	NULL
cases	NULL
had	NULL
counts	NULL
greater	NULL
than	NULL
4,000/uL	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Extramedullary	NULL
disease	NULL
,	NULL
including	NULL
hepatospleno-megaly	NULL
and	NULL
lymphadenopathy	NULL
,	NULL
was	NULL
noted	NULL
in	NULL
only	NULL
5	NULL
patients	NULL
;	NULL
among	NULL
18	NULL
patients	NULL
in	NULL
whom	NULL
central	NULL
nervous	NULL
system	NULL
(	NULL
CNS	NULL
)	NULL
involvement	NULL
was	NULL
assessed	NULL
,	NULL
none	NULL
displayed	NULL
evidence	NULL
of	NULL
CNS	NULL
involvement	NULL
at	NULL
presentation	NULL
or	NULL
relapse	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
AML-M3	NULL
patients	NULL
,	NULL
less	NULL
than	NULL
half	NULL
of	NULL
the	NULL
myeloid/NK	NULL
leukemia	NULL
patients	NULL
had	NULL
a	NULL
bleeding	NULL
diathesis	NULL
at	NULL
presentation	NULL
.	NULL

Eight	NULL
cases	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
had	NULL
a	NULL
mild	NULL
bleeding	NULL
diathesis	NULL
consisting	NULL
of	NULL
pete-chial	NULL
and/or	NULL
mucosal	NULL
hemorrhage	NULL
,	NULL
whereas	NULL
2	NULL
patients	NULL
displayed	NULL
disseminated	NULL
intravascular	NULL
coagulopathy	NULL
;	NULL
1	NULL
displayed	NULL
a	NULL
mild	NULL
bleeding	NULL
diathesis	NULL
(	NULL
case	NULL
12	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
and	NULL
1	NULL
a	NULL
moderate	NULL
diathesis	NULL
(	NULL
case	NULL
16	NULL
,	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Thirteen	NULL
patients	NULL
were	NULL
treated	NULL
with	NULL
standard-dose	NULL
cytosine	NULL
arabinoside	NULL
and	NULL
daunorubicin	NULL
(	NULL
8	NULL
on	NULL
SWOG	NULL
8600	NULL
,	NULL
3	NULL
on	NULL
SWOG	NULL
9031	NULL
,	NULL
and	NULL
2	NULL
off	NULL
protocol	NULL
)	NULL
and	NULL
three	NULL
with	NULL
standard-dose	NULL
cytosine	NULL
arabinoside	NULL
plus	NULL
idarubicin	NULL
(	NULL
2	NULL
on	NULL
SWOG	NULL
9034	NULL
and	NULL
1	NULL
off	NULL
protocol	NULL
)	NULL
.	NULL

The	NULL
other	NULL
four	NULL
patients	NULL
received	NULL
high-dose	NULL
cytosine	NULL
arabinoside	NULL
and	NULL
daunorubicin	NULL
on	NULL
SWOG	NULL
8600	NULL
(	NULL
2	NULL
with	NULL
2.0/g/M/d	NULL
x	NULL
6	NULL
days	NULL
and	NULL
2	NULL
with	NULL
3.0/g/M/d	NULL
x	NULL
6	NULL
days	NULL
)	NULL
.	NULL

Eleven	NULL
patients	NULL
achieved	NULL
complete	NULL
remission	NULL
(	NULL
CR	NULL
)	NULL
.	NULL

In	NULL
five	NULL
of	NULL
these	NULL
cases	NULL
,	NULL
relapse	NULL
occurred	NULL
after	NULL
90	NULL
days	NULL
,	NULL
98	NULL
days	NULL
,	NULL
15	NULL
months	NULL
,	NULL
16	NULL
months	NULL
,	NULL
or	NULL
27	NULL
months	NULL
;	NULL
the	NULL
other	NULL
six	NULL
patients	NULL
remain	NULL
alive	NULL
without	NULL
report	NULL
of	NULL
relapse	NULL
at	NULL
28	NULL
days	NULL
,	NULL
112	NULL
days	NULL
,	NULL
16	NULL
months	NULL
,	NULL
24	NULL
months	NULL
,	NULL
42	NULL
months	NULL
,	NULL
and	NULL
59	NULL
months	NULL
after	NULL
achieving	NULL
CR	NULL
.	NULL

Eleven	NULL
patients	NULL
have	NULL
died	NULL
and	NULL
the	NULL
other	NULL
nine	NULL
remain	NULL
alive	NULL
at	NULL
between	NULL
28	NULL
days	NULL
and	NULL
65	NULL
months	NULL
(	NULL
median	NULL
16	NULL
months	NULL
)	NULL
.	NULL

The	NULL
estimated	NULL
median	NULL
survival	NULL
is	NULL
30	NULL
months	NULL
.	NULL

Cytogenetic	NULL
review	NULL
.	NULL

Pretreatment	NULL
cytogenetic	NULL
studies	NULL
were	NULL
available	NULL
for	NULL
16/20	NULL
cases	NULL
and	NULL
12	NULL
of	NULL
these	NULL
cases	NULL
had	NULL
no	NULL
detectable	NULL
cytogenetic	NULL
abnormality	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

A	NULL
balanced	NULL
reciprocal	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q22	NULL
;	NULL
q1	NULL
1-21	NULL
)	NULL
is	NULL
a	NULL
characteristic	NULL
feature	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
;	NULL
AML-M3/M3v	NULL
)	NULL
and	NULL
is	NULL
detectable	NULL
in	NULL
50	NULL
%	NULL
to	NULL
70	NULL
%	NULL
of	NULL
APL	NULL
cases	NULL
by	NULL
standard	NULL
karyotypic	NULL
analysis	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
despite	NULL
the	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarities	NULL
between	NULL
our	NULL
cases	NULL
and	NULL
AML-M3v	NULL
,	NULL
no	NULL
case	NULL
contained	NULL
a	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
on	NULL
routine	NULL
cytogenetic	NULL
analysis	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Two	NULL
cases	NULL
had	NULL
karyotypic	NULL
abnormalities	NULL
involving	NULL
chromosome	NULL
17q	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
;	NULL
case	NULL
16	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
and	NULL
case	NULL
15	NULL
with	NULL
del	NULL
(	NULL
17	NULL
)	NULL
(	NULL
q25	NULL
)	NULL
.	NULL

Case	NULL
1	NULL
,	NULL
SCOTT	NULL
ET	NULL
AL	NULL
with	NULL
morphologic	NULL
features	NULL
most	NULL
consistent	NULL
with	NULL
FAB	NULL
AML-M7	NULL
was	NULL
characterized	NULL
by	NULL
a	NULL
47	NULL
,	NULL
XY	NULL
,	NULL
+8	NULL
,	NULL
t	NULL
(	NULL
16	NULL
;	NULL
21	NULL
)	NULL
(	NULL
pl1	NULL
;	NULL
q22	NULL
)	NULL
,	NULL
whereas	NULL
case	NULL
10	NULL
contained	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
14	NULL
)	NULL
(	NULL
p13	NULL
;	NULL
q11	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

RT-PCR	NULL
screen	NULL
for	NULL
the	NULL
PML-RARa	NULL
fusion	NULL
transcript	NULL
.	NULL

-	NULL
Because	NULL
of	NULL
the	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarities	NULL
of	NULL
our	NULL
cases	NULL
to	NULL
AML-M3v	NULL
and	NULL
because	NULL
of	NULL
the	NULL
preponderance	NULL
of	NULL
46.XY	NULL
or	NULL
46	NULL
,	NULL
XX	NULL
karyotypes	NULL
,	NULL
we	NULL
were	NULL
concerned	NULL
that	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
might	NULL
have	NULL
been	NULL
missed	NULL
in	NULL
routine	NULL
cytogenetic	NULL
analysis	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
used	NULL
RT-PCR	NULL
assays	NULL
to	NULL
screen	NULL
RNA	NULL
isolated	NULL
from	NULL
17	NULL
of	NULL
20	NULL
cases	NULL
with	NULL
residual	NULL
cells	NULL
(	NULL
all	NULL
cases	NULL
except	NULL
9	NULL
,	NULL
13	NULL
,	NULL
and	NULL
19	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
for	NULL
the	NULL
PML/RARa	NULL
chimeric	NULL
transcript	NULL
which	NULL
arises	NULL
from	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
.	NULL

All	NULL
RNA	NULL
samples	NULL
from	NULL
myeloid/NK	NULL
cases	NULL
and	NULL
from	NULL
three	NULL
APL	NULL
cases	NULL
with	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
used	NULL
as	NULL
controls	NULL
contained	NULL
amplifiable	NULL
32-microglobulin	NULL
transcripts	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
APL/FAB-M3	NULL
cases	NULL
(	NULL
Fig	NULL
4	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
lanes	NULL
12	NULL
through	NULL
14	NULL
)	NULL
,	NULL
all	NULL
17	NULL
of	NULL
the	NULL
myeloid/NK	NULL
leukemia	NULL
cases	NULL
analyzed	NULL
lacked	NULL
the	NULL
PML/	NULL
RARa	NULL
fusion	NULL
mRNA	NULL
(	NULL
Fig	NULL
4	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
lanes	NULL
2	NULL
through	NULL
11	NULL
;	NULL
data	NULL
on	NULL
remaining	NULL
cases	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
are	NULL
genetically	NULL
and	NULL
molec-ularly	NULL
distinct	NULL
from	NULL
APL/AML-M3	NULL
.	NULL

RT-PCR	NULL
screen	NULL
for	NULL
the	NULL
PLZF/RARa	NULL
fusion	NULL
transcript	NULL
.	NULL

The	NULL
AML-associated	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21.1	NULL
)	NULL
has	NULL
recently	NULL
been	NULL
cloned	NULL
and	NULL
characterized	NULL
.	NULL
``	NULL

Like	NULL
cases	NULL
of	NULL
true	NULL
APL	NULL
with	NULL
a	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
,	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
involves	NULL
the	NULL
RARa	NULL
gene	NULL
in	NULL
the	NULL
same	NULL
intron	NULL
on	NULL
chromosome	NULL
17q21	NULL
;	NULL
but	NULL
in	NULL
contrast	NULL
to	NULL
APL	NULL
,	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
results	NULL
in	NULL
a	NULL
fusion	NULL
of	NULL
RARa	NULL
with	NULL
a	NULL
novel	NULL
gene	NULL
designated	NULL
PLZF	NULL
on	NULL
chromosome	NULL
11423	NULL
.	NULL
``	NULL

As	NULL
one	NULL
of	NULL
our	NULL
cases	NULL
had	NULL
a	NULL
cytogenetically	NULL
detectable	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q21	NULL
;	NULL
q23	NULL
)	NULL
(	NULL
case	NULL
16	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
test	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
PLZF/RARa	NULL
fusion	NULL
transcript	NULL
in	NULL
this	NULL
case	NULL
,	NULL
and	NULL
to	NULL
determine	NULL
whether	NULL
any	NULL
of	NULL
the	NULL
other	NULL
cases	NULL
(	NULL
particularly	NULL
those	NULL
with	NULL
46	NULL
,	NULL
XX	NULL
or	NULL
46	NULL
,	NULL
XY	NULL
karyotypes	NULL
)	NULL
contained	NULL
a	NULL
PLZF/RARa	NULL
fusion	NULL
mRNA	NULL
.	NULL

RT-PCR	NULL
for	NULL
the	NULL
PLZF/RARa	NULL
fusion	NULL
mRNA	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
4D	NULL
,	NULL
detected	NULL
a	NULL
319-bp	NULL
PLZF/RARa	NULL
product	NULL
in	NULL
our	NULL
case	NULL
with	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
Fig	NULL
4D	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
as	NULL
well	NULL
as	NULL
in	NULL
a	NULL
positive	NULL
control	NULL
sample	NULL
.	NULL

However	NULL
,	NULL
none	NULL
of	NULL
the	NULL
eleven	NULL
other	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
tested	NULL
expressed	NULL
this	NULL
fusion	NULL
product	NULL
(	NULL
Fig	NULL
4D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
appears	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
myeloid/NK	NULL
leukemia	NULL
cell	NULL
phenotype	NULL
,	NULL
other	NULL
genetic	NULL
abnormalities	NULL
,	NULL
yet	NULL
to	NULL
be	NULL
defined	NULL
,	NULL
must	NULL
be	NULL
present	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
.	NULL

Response	NULL
of	NULL
cases	NULL
to	NULL
ATRA-Induced	NULL
differentiation	NULL
.	NULL

A	NULL
hallmark	NULL
of	NULL
APL	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
transcript	NULL
is	NULL
an	NULL
induction	NULL
of	NULL
differentiation	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

***	NULL
'	NULL
The	NULL
in	NULL
vitro	NULL
responsiveness	NULL
of	NULL
AML	NULL
cases	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
to	NULL
ATRA	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
determined	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarity	NULL
of	NULL
our	NULL
cases	NULL
to	NULL
APL	NULL
and	NULL
the	NULL
inclusion	NULL
of	NULL
one	NULL
case	NULL
with	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
involving	NULL
the	NULL
RARa	NULL
gene	NULL
in	NULL
our	NULL
series	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
the	NULL
responsiveness	NULL
of	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
to	NULL
ATRA	NULL
in	NULL
vitro	NULL
.	NULL

Residual	NULL
cryopreserved	NULL
cells	NULL
from	NULL
six	NULL
patients	NULL
(	NULL
Cases	NULL
3	NULL
,	NULL
11	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
and	NULL
19	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
all	NULL
of	NULL
whom	NULL
had	NULL
Ficoll-Hypaque	NULL
,	NULL
enriched	NULL
cryopreserved	NULL
blast	NULL
cell	NULL
percentages	NULL
exceeding	NULL
90	NULL
%	NULL
,	NULL
and	NULL
two	NULL
control	NULL
cases	NULL
of	NULL
APL/AML-M3	NULL
were	NULL
cultured	NULL
in	NULL
vitro	NULL
in	NULL
medium	NULL
with	NULL
or	NULL
without	NULL
ATRA	NULL
.	NULL

Morphologic	NULL
differentiation	NULL
was	NULL
assessed	NULL
at	NULL
time	NULL
0	NULL
and	NULL
on	NULL
days	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
postculture	NULL
.	NULL

ATRA-induced	NULL
granulocytic	NULL
differentiation	NULL
was	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
1	NULL
2	NULL
B3	NULL
4	NULL
5	NULL
6	NULL
251	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
<	NULL
104	NULL
bp	NULL
<	NULL
<	NULL
€326bp	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
l+	NULL
]	NULL
[	NULL
-	NULL
]	NULL
<	NULL
319	NULL
bp	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
RT-PCR	NULL
assays	NULL
for	NULL
PML/RARa	NULL
and	NULL
PLZF/RAR	NULL
«	NULL
fusion	NULL
transcripts	NULL
.	NULL

In	NULL
A	NULL
through	NULL
C	NULL
(	NULL
all	NULL
ethidium-stained	NULL
gels	NULL
of	NULL
RT-PCR	NULL
products	NULL
)	NULL
,	NULL
the	NULL
samples	NULL
in	NULL
each	NULL
lane	NULL
are	NULL
identical	NULL
:	NULL
lane	NULL
1	NULL
(	NULL
blank	NULL
control	NULL
)	NULL
;	NULL
lane	NULL
2	NULL
(	NULL
HL60	NULL
cells	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
)	NULL
;	NULL
lanes	NULL
3	NULL
through	NULL
11	NULL
(	NULL
myeloid/NK	NULL
leukemia	NULL
samples	NULL
)	NULL
;	NULL
lanes	NULL
12	NULL
and	NULL
13	NULL
(	NULL
APL/AML-M3	NULL
samples	NULL
with	NULL
a	NULL
PML/RARa-fusion	NULL
mRNA	NULL
involving	NULL
the	NULL
ber	NULL
1	NULL
)	NULL
;	NULL
lane	NULL
14	NULL
(	NULL
APL/AML-M3	NULL
sample	NULL
with	NULL
a	NULL
PML/RARa	NULL
fusion	NULL
involving	NULL
the	NULL
ber	NULL
3	NULL
PML	NULL
region	NULL
)	NULL
.	NULL
``	NULL

(	NULL
A	NULL
)	NULL
104-bp	NULL
RT-PCR	NULL
product	NULL
of	NULL
B2-microglobulin	NULL
mRNA	NULL
,	NULL
amplified	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
in	NULL
each	NULL
case	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Nested	NULL
RT-PCR	NULL
for	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
with	NULL
the	NULL
M2-R8	NULL
primers	NULL
(	NULL
B	NULL
)	NULL
,	NULL
which	NULL
detect	NULL
a	NULL
326-bp	NULL
PCR	NULL
product	NULL
arising	NULL
from	NULL
the	NULL
PML	NULL
ber	NULL
1	NULL
,	NULL
and	NULL
M4-R8	NULL
primers	NULL
(	NULL
C	NULL
)	NULL
,	NULL
which	NULL
detect	NULL
a	NULL
324-bp	NULL
PCR	NULL
product	NULL
arising	NULL
from	NULL
the	NULL
PML	NULL
ber3	NULL
)	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Compared	NULL
with	NULL
APL/AML-M3	NULL
controls	NULL
,	NULL
all	NULL
myeloid/NK	NULL
leukemia	NULL
cases	NULL
lack	NULL
the	NULL
PML/RARa	NULL
«	NULL
fusion	NULL
.	NULL

(	NULL
D	NULL
)	NULL
RT-PCR	NULL
analysis	NULL
with	NULL
primers	NULL
to	NULL
detect	NULL
the	NULL
PLZF/RARa-fusion	NULL
mRNA	NULL
.	NULL

Lanes	NULL
1	NULL
through	NULL
11	NULL
(	NULL
myeloid/NK	NULL
leukemia	NULL
cases	NULL
)	NULL
;	NULL
lane	NULL
12	NULL
(	NULL
myeloid/NK	NULL
leukemia	NULL
case	NULL
16	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
)	NULL
;	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
(	NULL
APL/AML-M3	NULL
controls	NULL
)	NULL
;	NULL
lane	NULL
15	NULL
(	NULL
[	NULL
+	NULL
]	NULL
,	NULL
AML	NULL
control	NULL
case	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
)	NULL
;	NULL
and	NULL
lane	NULL
16	NULL
(	NULL
[	NULL
-	NULL
]	NULL
,	NULL
blank	NULL
control	NULL
)	NULL
.	NULL

Lanes	NULL
12	NULL
and	NULL
15	NULL
show	NULL
a	NULL
319-	NULL
bp	NULL
PLZF/RARa-fusion	NULL
product	NULL
.	NULL

observed	NULL
in	NULL
none	NULL
of	NULL
the	NULL
six	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
,	NULL
including	NULL
case	NULL
16	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
with	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
both	NULL
control	NULL
APL/AML-M3	NULL
cases	NULL
showed	NULL
myelocytic	NULL
differentiation	NULL
with	NULL
decreased	NULL
blast	NULL
percentages	NULL
at	NULL
days	NULL
5	NULL
and	NULL
7	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
further	NULL
support	NULL
the	NULL
distinct	NULL
biologic	NULL
nature	NULL
of	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
and	NULL
confirm	NULL
the	NULL
nonresponsiveness	NULL
of	NULL
these	NULL
cases	NULL
to	NULL
ATRA	NULL
in	NULL
vitro	NULL
.	NULL

Assessment	NULL
of	NULL
NK	NULL
cell-mediated	NULL
functional	NULL
cytotoxicity	NULL
.	NULL

Because	NULL
the	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
coexpressed	NULL
the	NULL
CD56	NULL
and	NULL
CD11a	NULL
antigens	NULL
essential	NULL
for	NULL
functional	NULL
NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
in	NULL
addition	NULL
to	NULL
sharing	NULL
the	NULL
CD56	NULL
,	NULL
CD16~	NULL
phenotype	NULL
of	NULL
NK	NULL
precursor	NULL
cells	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
these	NULL
leukemic	NULL
cases	NULL
displayed	NULL
functional	NULL
NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL
``	NULL

Cytotoxicity	NULL
was	NULL
assessed	NULL
in	NULL
a	NULL
standard	NULL
*'Cr	NULL
release	NULL
functional	NULL
assay	NULL
using	NULL
the	NULL
NK	NULL
cell-susceptible	NULL
line	NULL
KS562	NULL
as	NULL
a	NULL
target	NULL
cell	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

Leukemic	NULL
blasts	NULL
from	NULL
six	NULL
cases	NULL
[	NULL
cases	NULL
3	NULL
,	NULL
10	NULL
(	NULL
results	NULL
obtained	NULL
with	NULL
relapse	NULL
material	NULL
)	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
and	NULL
19	NULL
;	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
]	NULL
were	NULL
added	NULL
as	NULL
effector	NULL
cells	NULL
;	NULL
in	NULL
each	NULL
case	NULL
selected	NULL
for	NULL
analysis	NULL
,	NULL
the	NULL
leukemic	NULL
blast	NULL
cell	NULL
percentage	NULL
in	NULL
the	NULL
enriched	NULL
cryopreserved	NULL
cell	NULL
suspensions	NULL
exceeded	NULL
90	NULL
%	NULL
and	NULL
no	NULL
cells	NULL
with	NULL
LGL	NULL
morphology	NULL
were	NULL
evident	NULL
in	NULL
the	NULL
preassay	NULL
or	NULL
postassay	NULL
samples	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
cytotoxicity	NULL
in	NULL
these	NULL
leukemic	NULL
samples	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
a	NULL
positive	NULL
control	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
IL-2-dependent	NULL
IMC-1	NULL
NK	NULL
leukemia	NULL
cell	NULL
line	NULL
that	NULL
displays	NULL
equal	NULL
or	NULL
increased	NULL
cytotoxicity	NULL
compared	NULL
with	NULL
freshly	NULL
isolated	NULL
PB	NULL
NK	NULL
cells	NULL
``	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
was	NULL
also	NULL
analyzed	NULL
in	NULL
two	NULL
cases	NULL
of	NULL
APL	NULL
with	NULL
a	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

Four	NULL
cases	NULL
(	NULL
cases	NULL
3	NULL
,	NULL
10	NULL
,	NULL
14	NULL
,	NULL
and	NULL
19	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
displayed	NULL
significant	NULL
cytotoxic	NULL
activity	NULL
with	NULL
IL-2	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
positive	NULL
NK	NULL
leukemia	NULL
control	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
5	NULL
;	NULL
showing	NULL
the	NULL
data	NULL
from	NULL
case	NULL
14	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
both	NULL
cases	NULL
of	NULL
APL/FAB	NULL
M3	NULL
lacked	NULL
cytotoxic	NULL
activity	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

This	NULL
demonstration	NULL
of	NULL
functional	NULL
cell-mediated	NULL
cytotoxicity	NULL
in	NULL
the	NULL
leukemic	NULL
cells	NULL
further	NULL
supports	NULL
a	NULL
relationship	NULL
between	NULL
myeloid/NK	NULL
acute	NULL
leukemias	NULL
and	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
NK	NULL
lineage	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16°	NULL
nonleukemic	NULL
counterpart	NULL
cell	NULL
.	NULL

Although	NULL
our	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
expressed	NULL
the	NULL
CD56*	NULL
,	NULL
CD16~	NULL
phenotype	NULL
of	NULL
NK	NULL
precursor	NULL
cells	NULL
,	NULL
they	NULL
also	NULL
coexpressed	NULL
the	NULL
myeloid-associated	NULL
antigen	NULL
CD33	NULL
.	NULL

As	NULL
previous	NULL
studies	NULL
characterizing	NULL
CD56	NULL
,	NULL
CD16~	NULL
NK	NULL
precursor	NULL
cells	NULL
have	NULL
not	NULL
included	NULL
an	NULL
analysis	NULL
of	NULL
myeloid	NULL
antigens	NULL
such	NULL
as	NULL
CD33	NULL
,	NULL
``	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
coexpression	NULL
of	NULL
CD33	NULL
in	NULL
our	NULL
cases	NULL
reflected	NULL
an	NULL
aberrant	NULL
leukemic	NULL
phenotype	NULL
or	NULL
whether	NULL
a	NULL
CD33¢*	NULL
,	NULL
CD56	NULL
,	NULL
CD16~	NULL
myeloid/NK	NULL
cell	NULL
was	NULL
present	NULL
in	NULL
normal	NULL
BM	NULL
and	NULL
PB	NULL
.	NULL

Using	NULL
PB	NULL
buffy	NULL
coats	NULL
from	NULL
four	NULL
healthy	NULL
donors	NULL
,	NULL
a	NULL
three-step	NULL
isolation	NULL
process	NULL
was	NULL
performed	NULL
to	NULL
enrich	NULL
for	NULL
NK	NULL
cells	NULL
.	NULL

Cells	NULL
obtained	NULL
by	NULL
these	NULL
methods	NULL
were	NULL
labeled	NULL
with	NULL
CD33	NULL
,	NULL
CD56	NULL
,	NULL
and	NULL
CD16	NULL
antibodies	NULL
and	NULL
sorted	NULL
using	NULL
multiparameter	NULL
flow	NULL
cytometry	NULL
.	NULL

From	NULL
plots	NULL
of	NULL
forward-angle	NULL
light	NULL
scat	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

252	NULL
80	NULL
=_	NULL
70	NULL
|-	NULL
z	NULL
T	NULL
1	NULL
*	NULL
60	NULL
|_	NULL
0	NULL
Fa	NULL
I	NULL
50	NULL
I	NULL
»	NULL
6	NULL
9	NULL
+	NULL
G	NULL
40	NULL
|	NULL
§	NULL
&	NULL
w	NULL
e	NULL
a	NULL
6	NULL
®	NULL
5p	NULL
|_	NULL
i	NULL
10	NULL
|-	NULL
CJ	NULL
0	NULL
&	NULL
_	NULL
ind	NULL
Alin	NULL
il	NULL
``	NULL
§§	NULL
50	NULL
:	NULL
1	NULL
25:1	NULL
12.5:1	NULL
6:1	NULL
3:1	NULL
Effector/Target	NULL
Ratio	NULL
Fig	NULL
5	NULL
.	NULL

In	NULL
vitro	NULL
functional	NULL
cell-mediated	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

(	NULL
@	NULL
)	NULL
,	NULL
the	NULL
IMC-1	NULL
NK	NULL
cell	NULL
line	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
;	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
leukemic	NULL
blasts	NULL
from	NULL
a	NULL
myeloid/NK	NULL
leukemia	NULL
sample	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
case	NULL
14	NULL
)	NULL
cultured	NULL
without	NULL
IL-2	NULL
;	NULL
(	NULL
M	NULL
)	NULL
,	NULL
blasts	NULL
from	NULL
the	NULL
same	NULL
myeloid/NK	NULL
leukemic	NULL
sample	NULL
cultured	NULL
for	NULL
48	NULL
hours	NULL
in	NULL
IL-2	NULL
;	NULL
(	NULL
A	NULL
)	NULL
,	NULL
leukemic	NULL
blasts	NULL
from	NULL
an	NULL
APL	NULL
sample	NULL
with	NULL
a	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
cultured	NULL
without	NULL
IL-2	NULL
;	NULL
(	NULL
A	NULL
)	NULL
,	NULL
leukemic	NULL
blasts	NULL
from	NULL
the	NULL
sample	NULL
APL	NULL
sample	NULL
cultured	NULL
for	NULL
48	NULL
hours	NULL
in	NULL
IL-2	NULL
.	NULL

Like	NULL
the	NULL
IMC-1	NULL
NK	NULL
control	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
leukemic	NULL
blasts	NULL
from	NULL
the	NULL
myeloid/NK	NULL
leukemia	NULL
sample	NULL
showed	NULL
significant	NULL
cytotoxicity	NULL
against	NULL
K562	NULL
target	NULL
cells	NULL
with	NULL
IL-2	NULL
stimulation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
APL/FAB	NULL
M3	NULL
sample	NULL
lacked	NULL
functional	NULL
cell-mediated	NULL
cytotoxicity	NULL
with	NULL
or	NULL
without	NULL
IL-2	NULL
.	NULL

ter	NULL
versus	NULL
side	NULL
scatter	NULL
,	NULL
a	NULL
population	NULL
of	NULL
intermediately-sized	NULL
cells	NULL
with	NULL
low	NULL
side	NULL
scatter	NULL
(	NULL
Fig	NULL
6A	NULL
,	NULL
see	NULL
page	NULL
249	NULL
)	NULL
was	NULL
selected	NULL
for	NULL
flow	NULL
cytometric	NULL
sorting	NULL
using	NULL
a	NULL
Coulter	NULL
753	NULL
flow	NULL
cytometer	NULL
.	NULL

From	NULL
these	NULL
sorting	NULL
experiments	NULL
,	NULL
a	NULL
population	NULL
of	NULL
CD33*	NULL
,	NULL
moderately	NULL
bright	NULL
CD56*	NULL
,	NULL
CD16~	NULL
cells	NULL
was	NULL
obtained	NULL
in	NULL
each	NULL
sample	NULL
(	NULL
Fig	NULL
6	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
that	NULL
used	NULL
FACscan	NULL
flow	NULL
cytometry	NULL
with	NULL
log	NULL
scale	NULL
of	NULL
4	NULL
have	NULL
shown	NULL
that	NULL
CD16~	NULL
NK	NULL
cells	NULL
are	NULL
predominantly	NULL
CD56	NULL
brightly	NULL
positive	NULL
.	NULL

The	NULL
use	NULL
of	NULL
log	NULL
3	NULL
data	NULL
in	NULL
our	NULL
study	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
log	NULL
4	NULL
data	NULL
,	NULL
tends	NULL
to	NULL
compress	NULL
the	NULL
data	NULL
toward	NULL
the	NULL
X-axis	NULL
and	NULL
therefore	NULL
the	NULL
flourescence	NULL
intensity	NULL
shift	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
as	NULL
great	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
Coulter	NULL
753	NULL
flow	NULL
cytometer	NULL
and	NULL
the	NULL
log	NULL
3	NULL
scale	NULL
setting	NULL
,	NULL
although	NULL
our	NULL
data	NULL
can	NULL
not	NULL
be	NULL
directly	NULL
compared	NULL
with	NULL
La-nier	NULL
's	NULL
study	NULL
,	NULL
we	NULL
believe	NULL
that	NULL
our	NULL
data	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
findings	NULL
of	NULL
that	NULL
study	NULL
.	NULL

We	NULL
calculate	NULL
these	NULL
cells	NULL
to	NULL
be	NULL
present	NULL
at	NULL
a	NULL
frequency	NULL
of	NULL
approximately	NULL
1	NULL
%	NULL
to	NULL
2	NULL
%	NULL
of	NULL
PB	NULL
mononuclear	NULL
cells	NULL
in	NULL
healthy	NULL
adults	NULL
.	NULL

The	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
of	NULL
the	NULL
sorted	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
population	NULL
showed	NULL
features	NULL
of	NULL
NK	NULL
or	NULL
LGLs	NULL
with	NULL
irregular	NULL
or	NULL
invaginated	NULL
nuclear	NULL
membranes	NULL
with	NULL
coarsely	NULL
clumped	NULL
chromatin	NULL
and	NULL
abundant	NULL
slightly	NULL
basophilic	NULL
cytoplasm	NULL
containing	NULL
scattered	NULL
small	NULL
azurophilic	NULL
granules	NULL
.	NULL

These	NULL
cells	NULL
did	NULL
not	NULL
stain	NULL
with	NULL
nonspecific	NULL
esterase	NULL
stains	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
distinguishing	NULL
them	NULL
from	NULL
CDS56+*	NULL
monocytic	NULL
cells	NULL
.	NULL
``	NULL

Comparison	NULL
of	NULL
the	NULL
morphologic	NULL
features	NULL
of	NULL
these	NULL
normal	NULL
sorted	NULL
CD33*	NULL
,	NULL
CDS56*	NULL
,	NULL
CD16~	NULL
PB	NULL
cells	NULL
(	NULL
Fig	NULL
6D	NULL
)	NULL
to	NULL
those	NULL
of	NULL
the	NULL
CD33	NULL
#	NULL
*	NULL
,	NULL
CD56	NULL
,	NULL
CD16~	NULL
leukemic	NULL
cells	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
show	NULL
striking	NULL
similarities	NULL
:	NULL
moderately	NULL
high	NULL
nuclear	NULL
to	NULL
cytoplasmic	NULL
ratios	NULL
,	NULL
irregular	NULL
nuclear	NULL
membrane	NULL
contours	NULL
,	NULL
and	NULL
scant	NULL
azurophilic	NULL
cytoplasmic	NULL
granulation	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
normal	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
myeloid/	NULL
NK	NULL
cell	NULL
population	NULL
in	NULL
the	NULL
PB	NULL
of	NULL
normal	NULL
individuals	NULL
.	NULL

SCOTT	NULL
ET	NULL
AL	NULL
DISCUSSION	NULL
We	NULL
have	NULL
characterized	NULL
a	NULL
previously	NULL
unrecognized	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
with	NULL
unique	NULL
morphologic	NULL
,	NULL
immunophenotypic	NULL
,	NULL
cytogenetic	NULL
,	NULL
and	NULL
functional	NULL
biologic	NULL
features	NULL
.	NULL

These	NULL
20	NULL
adult	NULL
de	NULL
novo	NULL
acute	NULL
leukemia	NULL
cases	NULL
were	NULL
characterized	NULL
by	NULL
the	NULL
coexpression	NULL
of	NULL
myeloid-associated	NULL
(	NULL
CD33	NULL
,	NULL
CD13	NULL
,	NULL
CD15	NULL
)	NULL
and	NULL
NK	NULL
cell-associated	NULL
(	NULL
CD56	NULL
)	NULL
antigens	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
HLA-DR	NULL
and	NULL
the	NULL
T-cell-associated	NULL
antigens	NULL
CD3	NULL
and	NULL
CD8	NULL
.	NULL

Despite	NULL
their	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarity	NULL
to	NULL
cases	NULL
of	NULL
APL/FAB	NULL
M3v	NULL
,	NULL
these	NULL
cases	NULL
lacked	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
the	NULL
resultant	NULL
PML/RARa	NULL
fusion	NULL
transcript	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
case	NULL
showed	NULL
a	NULL
differentiation-induction	NULL
response	NULL
to	NULL
ATRA	NULL
in	NULL
vitro	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
cases	NULL
of	NULL
true	NULL
APL	NULL
with	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
transcript	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
these	NULL
acute	NULL
leukemia	NULL
cases	NULL
may	NULL
account	NULL
for	NULL
some	NULL
cases	NULL
of	NULL
APL	NULL
that	NULL
have	NULL
not	NULL
responded	NULL
to	NULL
ATRA	NULL
.	NULL
``	NULL

°	NULL
Because	NULL
these	NULL
CD33*	NULL
,	NULL
CD56	NULL
,	NULL
CD16~	NULL
acute	NULL
leukemias	NULL
showed	NULL
functional	NULL
NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
and	NULL
because	NULL
we	NULL
were	NULL
able	NULL
to	NULL
identify	NULL
a	NULL
normal	NULL
CD33	NULL
#	NULL
*	NULL
,	NULL
CDS56*	NULL
,	NULL
CD16~	NULL
counterpart	NULL
cell	NULL
in	NULL
the	NULL
PB	NULL
of	NULL
healthy	NULL
individuals	NULL
,	NULL
we	NULL
further	NULL
suggest	NULL
these	NULL
acute	NULL
leukemia	NULL
cases	NULL
may	NULL
arise	NULL
from	NULL
transformation	NULL
of	NULL
a	NULL
precursor	NULL
cell	NULL
common	NULL
to	NULL
the	NULL
myeloid	NULL
and	NULL
NK	NULL
cell	NULL
lineages	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
have	NULL
chosen	NULL
to	NULL
designate	NULL
this	NULL
type	NULL
of	NULL
leukemia	NULL
as	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
.	NULL

Historically	NULL
,	NULL
NK	NULL
cell	NULL
leukemia	NULL
has	NULL
been	NULL
considered	NULL
a	NULL
subset	NULL
of	NULL
LGL	NULL
lymphoproliferative	NULL
disorders	NULL
,	NULL
characterized	NULL
by	NULL
an	NULL
indolent	NULL
or	NULL
chronic	NULL
clinical	NULL
course	NULL
.	NULL
``	NULL

It	NULL
seems	NULL
inappropriate	NULL
to	NULL
include	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemia	NULL
,	NULL
a	NULL
more	NULL
aggressive	NULL
disease	NULL
with	NULL
a	NULL
distinct	NULL
non-T-	NULL
,	NULL
non-B-cell	NULL
immu-nophenotype	NULL
,	NULL
as	NULL
a	NULL
subtype	NULL
of	NULL
this	NULL
disease	NULL
.	NULL

True	NULL
human	NULL
NK	NULL
cell-lineage	NULL
acute	NULL
leukemias	NULL
are	NULL
rare	NULL
;	NULL
to	NULL
date	NULL
,	NULL
only	NULL
a	NULL
few	NULL
well-characterized	NULL
cases	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
the	NULL
litera-ture	NULL
.	NULL

``	NULL
**	NULL
Until	NULL
recently	NULL
,	NULL
the	NULL
literature	NULL
regarding	NULL
LGL	NULL
disorders	NULL
has	NULL
been	NULL
confusing	NULL
,	NULL
partly	NULL
because	NULL
of	NULL
numerous	NULL
proposed	NULL
classification	NULL
schemes	NULL
and	NULL
to	NULL
a	NULL
paucity	NULL
of	NULL
detailed	NULL
molecular	NULL
,	NULL
genetic	NULL
,	NULL
and	NULL
immunophenotypic	NULL
data	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
review	NULL
,	NULL
``	NULL
``	NULL
Loughran	NULL
provides	NULL
a	NULL
basis	NULL
for	NULL
a	NULL
uniform	NULL
classification	NULL
of	NULL
LGL	NULL
disorders	NULL
that	NULL
is	NULL
based	NULL
on	NULL
reproducible	NULL
clinical	NULL
and	NULL
clonal	NULL
features	NULL
:	NULL
LGL	NULL
disorders	NULL
are	NULL
divided	NULL
into	NULL
three	NULL
distinct	NULL
subgroups	NULL
designated	NULL
T-LGL	NULL
leukemia	NULL
(	NULL
clonal	NULL
CD3*	NULL
)	NULL
,	NULL
NK-LGL	NULL
leukemia	NULL
(	NULL
clonal	NULL
CD3T	NULL
)	NULL
,	NULL
and	NULL
LGL	NULL
lymphocytosis	NULL
(	NULL
nonclonal	NULL
CD3*	NULL
or	NULL
CD3T	NULL
)	NULL
.	NULL

The	NULL
myeloid/NK	NULL
acute	NULL
leukemias	NULL
that	NULL
we	NULL
describe	NULL
in	NULL
this	NULL
report	NULL
are	NULL
most	NULL
similar	NULL
to	NULL
the	NULL
NK-LGL	NULL
subgroup	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
whereas	NULL
the	NULL
acute	NULL
clinical	NULL
presentation	NULL
,	NULL
equal	NULL
sex	NULL
distribution	NULL
,	NULL
and	NULL
CD3~	NULL
clonality	NULL
of	NULL
NK-LGL	NULL
leukemia	NULL
may	NULL
resemble	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
,	NULL
comparison	NULL
of	NULL
other	NULL
features	NULL
shows	NULL
that	NULL
these	NULL
two	NULL
diseases	NULL
are	NULL
distinct	NULL
.	NULL

Although	NULL
9/18	NULL
of	NULL
the	NULL
myeloid/	NULL
NK	NULL
leukemia	NULL
cases	NULL
had	NULL
a	NULL
mild	NULL
to	NULL
moderate	NULL
absolute	NULL
increase	NULL
in	NULL
PB	NULL
lymphocytes	NULL
,	NULL
only	NULL
rare	NULL
cases	NULL
showed	NULL
an	NULL
absolute	NULL
increase	NULL
in	NULL
PB	NULL
and	NULL
BM	NULL
cells	NULL
with	NULL
LGL	NULL
morphology	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NK-LGL	NULL
leukemia	NULL
consistently	NULL
presents	NULL
with	NULL
an	NULL
absolute	NULL
lymphocytosis	NULL
(	NULL
greater	NULL
than	NULL
4,000/uL	NULL
)	NULL
and	NULL
displays	NULL
frequent	NULL
and	NULL
rapid	NULL
increases	NULL
in	NULL
LGL	NULL
counts	NULL
(	NULL
greater	NULL
than	NULL
50,000/uL	NULL
)	NULL
.	NULL

``	NULL
°	NULL
Coagulopathy	NULL
is	NULL
also	NULL
more	NULL
common	NULL
and	NULL
severe	NULL
in	NULL
NK-LGL	NULL
leukemia	NULL
.	NULL
``	NULL

Other	NULL
features	NULL
not	NULL
shared	NULL
with	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
include	NULL
massive	NULL
hepatospleno-megaly	NULL
and	NULL
involvement	NULL
of	NULL
the	NULL
gastrointestinal	NULL
tract	NULL
with	NULL
jaundice	NULL
and	NULL
ascites	NULL
.	NULL

The	NULL
characteristic	NULL
morphologic	NULL
feature	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
of	NULL
NK-LGL	NULL
leukemia	NULL
is	NULL
the	NULL
presence	NULL
of	NULL
increased	NULL
PB	NULL
and	NULL
BM	NULL
cells	NULL
with	NULL
LGL	NULL
morphology	NULL
with	NULL
or	NULL
without	NULL
coarse	NULL
cytoplasmic	NULL
granules	NULL
,	NULL
rather	NULL
than	NULL
the	NULL
unique	NULL
blast	NULL
cell	NULL
features	NULL
of	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
.	NULL

The	NULL
immunophenotype	NULL
of	NULL
NK-LGL	NULL
leukemia	NULL
(	NULL
CD3~	NULL
,	NULL
CD56*	NULL
,	NULL
CD25~	NULL
,	NULL
CD16*	NULL
,	NULL
and	NULL
CD57*	NULL
)	NULL
is	NULL
also	NULL
distinctly	NULL
different	NULL
from	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
.	NULL

Although	NULL
expression	NULL
of	NULL
stem	NULL
cell	NULL
,	NULL
myeloid-associ-ated	NULL
,	NULL
and	NULL
adhesion	NULL
molecules	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
thoroughly	NULL
studied	NULL
in	NULL
NK-LGL	NULL
leukemia	NULL
,	NULL
the	NULL
HLA-DR*/CD56*	NULL
NK-LGL	NULL
leukemia	NULL
cases	NULL
reported	NULL
by	NULL
Imamura®	NULL
were	NULL
CD13-	NULL
and	NULL
CD33-negative	NULL
,	NULL
supporting	NULL
our	NULL
theory	NULL
that	NULL
NK-LGL	NULL
leukemia	NULL
and	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
are	NULL
separate	NULL
and	NULL
distinct	NULL
diseases	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
,	NULL
many	NULL
clonal	NULL
NK-LGL	NULL
cases	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
have	NULL
simple	NULL
or	NULL
complex	NULL
abnormalities	NULL
of	NULL
chromosome	NULL
5.5	NULL
``	NULL
Finally	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
majority	NULL
of	NULL
our	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
,	NULL
most	NULL
NK-LGL	NULL
leukemia	NULL
patients	NULL
have	NULL
had	NULL
rapidly	NULL
progressive	NULL
clinical	NULL
courses	NULL
and	NULL
have	NULL
died	NULL
within	NULL
several	NULL
months	NULL
of	NULL
presentation	NULL
despite	NULL
aggressive	NULL
treatment	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
the	NULL
myeloid/NK	NULL
acute	NULL
leukemias	NULL
that	NULL
we	NULL
present	NULL
in	NULL
this	NULL
report	NULL
and	NULL
cases	NULL
of	NULL
NK-LGL	NULL
leukemia	NULL
have	NULL
some	NULL
shared	NULL
features	NULL
and	NULL
both	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
NK	NULL
cell	NULL
lineage	NULL
,	NULL
distinct	NULL
biologic	NULL
and	NULL
clinical	NULL
differences	NULL
are	NULL
apparent	NULL
.	NULL

All	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
expressed	NULL
the	NULL
CD56	NULL
antigen	NULL
at	NULL
high	NULL
density	NULL
.	NULL

CD56	NULL
is	NULL
an	NULL
isoform	NULL
of	NULL
the	NULL
well-characterized	NULL
NCAM	NULL
that	NULL
mediates	NULL
cell/cell	NULL
adhesive	NULL
inter-actions	NULL
.	NULL
``	NULL

''	NULL
CD56*	NULL
,	NULL
CD16+	NULL
NK	NULL
cells	NULL
express	NULL
a	NULL
variantly	NULL
spliced	NULL
form	NULL
of	NULL
CD56	NULL
that	NULL
mediates	NULL
NK	NULL
cell-target	NULL
binding	NULL
.	NULL
``	NULL

Expression	NULL
of	NULL
CD56	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
CD11a	NULL
adhesion	NULL
molecule	NULL
also	NULL
expressed	NULL
on	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
,	NULL
is	NULL
required	NULL
for	NULL
NK	NULL
cell-mediated	NULL
cytotoxic	NULL
effector	NULL
function	NULL
.	NULL
``	NULL

''	NULL
In	NULL
addition	NULL
to	NULL
the	NULL
characteristic	NULL
expression	NULL
of	NULL
CD56	NULL
on	NULL
normal	NULL
NK	NULL
cells	NULL
,	NULL
CD56	NULL
is	NULL
also	NULL
expressed	NULL
on	NULL
a	NULL
subset	NULL
of	NULL
CD3	NULL
*	NULL
cytotoxic	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
a	NULL
subset	NULL
of	NULL
PB	NULL
mono-cytes	NULL
.	NULL

``	NULL
**	NULL
In	NULL
hematopoietic	NULL
neoplasms	NULL
,	NULL
CD56	NULL
has	NULL
also	NULL
been	NULL
detected	NULL
on	NULL
clinically	NULL
aggressive	NULL
T-cell	NULL
lymphomas	NULL
,	NULL
plasma	NULL
cell	NULL
myelomas	NULL
,	NULL
and	NULL
de	NULL
novo	NULL
AML	NULL
s	NULL
with	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
,	NULL
t	NULL
(	NULL
8	NULL
;	NULL
16	NULL
)	NULL
,	NULL
and	NULL
other	NULL
monocytic	NULL
leukemia-associated	NULL
cytogenetic	NULL
abnor-malities	NULL
.	NULL
``	NULL

The	NULL
forms	NULL
of	NULL
CD56	NULL
expressed	NULL
by	NULL
various	NULL
hematopoietic	NULL
neoplasms	NULL
are	NULL
highly	NULL
variable	NULL
as	NULL
a	NULL
result	NULL
of	NULL
both	NULL
alternative	NULL
splicing	NULL
and	NULL
differential	NULL
glycosylation	NULL
``	NULL
``	NULL
;	NULL
these	NULL
alternative	NULL
isoforms	NULL
may	NULL
account	NULL
in	NULL
part	NULL
for	NULL
the	NULL
different	NULL
biologic	NULL
behaviors	NULL
of	NULL
CDS6*®	NULL
neoplasms	NULL
.	NULL

Expression	NULL
of	NULL
CD16	NULL
is	NULL
not	NULL
uniform	NULL
in	NULL
cells	NULL
of	NULL
NK	NULL
lineage	NULL
and	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
NK	NULL
cell	NULL
function	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
initial	NULL
reports	NULL
of	NULL
diminished	NULL
cytotoxicity	NULL
of	NULL
CD56*	NULL
,	NULL
CD16~	NULL
NK	NULL
cells	NULL
,	NULL
subsequent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
CD56	NULL
,	NULL
CD16~	NULL
NK	NULL
cells	NULL
may	NULL
have	NULL
increased	NULL
cytotoxicity	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
CD16	NULL
in	NULL
our	NULL
cases	NULL
does	NULL
not	NULL
preclude	NULL
NK	NULL
cell	NULL
lineage	NULL
and	NULL
the	NULL
cytotoxicity	NULL
shown	NULL
by	NULL
our	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
,	NULL
CD11a*	NULL
cases	NULL
is	NULL
not	NULL
unexpected	NULL
.	NULL

Although	NULL
the	NULL
majority	NULL
of	NULL
PB	NULL
NK	NULL
cells	NULL
coexpress	NULL
CD56	NULL
and	NULL
CD16	NULL
,	NULL
a	NULL
CD56*	NULL
,	NULL
CD16~	NULL
NK	NULL
cell	NULL
population	NULL
has	NULL
been	NULL
identified	NULL
at	NULL
frequency	NULL
of	NULL
less	NULL
than	NULL
2	NULL
%	NULL
in	NULL
normal	NULL
PB	NULL
.	NULL
``	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
CD56*	NULL
NK	NULL
cells	NULL
that	NULL
are	NULL
CD16~	NULL
or	NULL
CD16	NULL
``	NULL
are	NULL
NK	NULL
cell	NULL
precursors	NULL
because	NULL
these	NULL
CD56*	NULL
,	NULL
CD16~	NULL
cells	NULL
comprise	NULL
the	NULL
majority	NULL
of	NULL
NK	NULL
cells	NULL
found	NULL
in	NULL
the	NULL
BM	NULL
and	NULL
splenic	NULL
pools	NULL
.	NULL

***	NULL
``	NULL
Natural	NULL
killer	NULL
cells	NULL
with	NULL
a	NULL
similar	NULL
phenotype	NULL
have	NULL
also	NULL
been	NULL
generated	NULL
from	NULL
primitive	NULL
CD34*	NULL
,	NULL
253	NULL
HLA-DR~	NULL
progenitors	NULL
in	NULL
long-term	NULL
BM	NULL
cultures	NULL
supplemented	NULL
with	NULL
IL-2	NULL
.	NULL

*	NULL
``	NULL
Unfortunately	NULL
,	NULL
the	NULL
coexpression	NULL
of	NULL
myeloid-associated	NULL
antigens	NULL
has	NULL
not	NULL
been	NULL
examined	NULL
in	NULL
most	NULL
NK	NULL
cell	NULL
studies	NULL
;	NULL
thus	NULL
,	NULL
we	NULL
can	NULL
not	NULL
determine	NULL
whether	NULL
the	NULL
CD56	NULL
,	NULL
CD16~	NULL
NK	NULL
precursor	NULL
cells	NULL
identified	NULL
in	NULL
those	NULL
studies	NULL
correspond	NULL
to	NULL
or	NULL
are	NULL
distinct	NULL
from	NULL
the	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
leukemic	NULL
cells	NULL
that	NULL
we	NULL
have	NULL
identified	NULL
in	NULL
this	NULL
report	NULL
.	NULL

As	NULL
NK	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
be	NULL
BM-derived	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
the	NULL
normal	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
cells	NULL
that	NULL
we	NULL
have	NULL
identified	NULL
may	NULL
be	NULL
a	NULL
precursor	NULL
population	NULL
common	NULL
to	NULL
the	NULL
myeloid	NULL
and	NULL
NK	NULL
cell	NULL
lineage	NULL
.	NULL
``	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
the	NULL
growth	NULL
factor	NULL
dependence	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
future	NULL
studies	NULL
,	NULL
and	NULL
whether	NULL
the	NULL
CD33	NULL
antigen	NULL
is	NULL
lost	NULL
upon	NULL
culture	NULL
of	NULL
these	NULL
cells	NULL
with	NULL
IL-2	NULL
that	NULL
may	NULL
promote	NULL
further	NULL
differentiation	NULL
into	NULL
the	NULL
NK	NULL
lineage	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
the	NULL
CD33	NULL
,	NULL
CD56*	NULL
,	NULL
CD16	NULL
``	NULL
acute	NULL
leukemias	NULL
that	NULL
we	NULL
have	NULL
identified	NULL
may	NULL
represent	NULL
leukemic	NULL
transformation	NULL
of	NULL
this	NULL
normal	NULL
CD33*	NULL
,	NULL
CD56*	NULL
,	NULL
CD16~	NULL
normal	NULL
counterpart	NULL
cell	NULL
.	NULL

Despite	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarities	NULL
,	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
lacked	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
and	NULL
failed	NULL
to	NULL
show	NULL
a	NULL
differentiation-induction	NULL
response	NULL
to	NULL
ATRA	NULL
in	NULL
vitro	NULL
.	NULL

Distinguishing	NULL
these	NULL
myeloid/NK	NULL
acute	NULL
leukemias	NULL
from	NULL
cases	NULL
of	NULL
true	NULL
APL	NULL
will	NULL
be	NULL
important	NULL
for	NULL
clinical	NULL
studies	NULL
of	NULL
ATRA	NULL
.	NULL

De	NULL
Rossi	NULL
et	NULL
al	NULL
``	NULL
have	NULL
proposed	NULL
that	NULL
immunophenotypic/flow	NULL
cytometric	NULL
analysis	NULL
could	NULL
be	NULL
used	NULL
to	NULL
make	NULL
a	NULL
precise	NULL
diagnosis	NULL
of	NULL
APL	NULL
;	NULL
the	NULL
diagnostic	NULL
profile	NULL
proposed	NULL
was	NULL
CD33*	NULL
,	NULL
CD13*	NULL
,	NULL
CD9*	NULL
(	NULL
a	NULL
B-cell	NULL
and	NULL
granulocytic	NULL
marker	NULL
)	NULL
,	NULL
HLA-DR~	NULL
,	NULL
and	NULL
CD7~	NULL
.	NULL

Unfortunately	NULL
,	NULL
the	NULL
immunophenotypic	NULL
studies	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
show	NULL
that	NULL
this	NULL
profile	NULL
would	NULL
not	NULL
distingnish	NULL
cases	NULL
of	NULL
true	NULL
APL	NULL
from	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemia	NULL
cases	NULL
.	NULL

Our	NULL
studies	NULL
suggest	NULL
that	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemias	NULL
could	NULL
be	NULL
distinguished	NULL
from	NULL
cases	NULL
of	NULL
true	NULL
APL	NULL
by	NULL
inclusion	NULL
of	NULL
the	NULL
CD56	NULL
and	NULL
CD16	NULL
antigens	NULL
in	NULL
the	NULL
proposed	NULL
diagnostic	NULL
panel	NULL
.	NULL

However	NULL
,	NULL
this	NULL
immunophenotypic	NULL
approach	NULL
may	NULL
still	NULL
not	NULL
allow	NULL
precise	NULL
di-agnosis	NULL
;	NULL
in	NULL
a	NULL
review	NULL
of	NULL
the	NULL
immunophenotypic	NULL
data	NULL
of	NULL
50	NULL
SWOG	NULL
APL/AML-M3	NULL
cases	NULL
[	NULL
(	NULL
with	NULL
a	NULL
confirmed	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
]	NULL
,	NULL
we	NULL
identified	NULL
two	NULL
APL	NULL
cases	NULL
with	NULL
expression	NULL
of	NULL
CD56	NULL
at	NULL
high	NULL
antigen	NULL
density	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
propose	NULL
that	NULL
all	NULL
acute	NULL
leukemia	NULL
cases	NULL
with	NULL
morphologic	NULL
features	NULL
similar	NULL
to	NULL
APL	NULL
be	NULL
initially	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometric	NULL
immunophenotyping	NULL
using	NULL
a	NULL
panel	NULL
that	NULL
includes	NULL
the	NULL
HLA-DR	NULL
,	NULL
CD34	NULL
,	NULL
CD33	NULL
,	NULL
CD15	NULL
,	NULL
CD16	NULL
,	NULL
CD56	NULL
,	NULL
and	NULL
CD11a	NULL
antigens	NULL
,	NULL
and	NULL
by	NULL
careful	NULL
morphologic	NULL
examination	NULL
with	NULL
rigid	NULL
adherence	NULL
to	NULL
criteria	NULL
for	NULL
AML-M3/M3v	NULL
.	NULL

Diagnostic	NULL
confirmation	NULL
of	NULL
APL	NULL
versus	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
should	NULL
include	NULL
RT-PCR	NULL
studies	NULL
to	NULL
assess	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
transcript	NULL
.	NULL

With	NULL
the	NULL
morphologic	NULL
and	NULL
immunophenotypic	NULL
similarity	NULL
of	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
to	NULL
APL	NULL
,	NULL
it	NULL
is	NULL
of	NULL
interest	NULL
that	NULL
one	NULL
of	NULL
our	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
that	NULL
results	NULL
in	NULL
fusion	NULL
of	NULL
the	NULL
RARa	NULL
and	NULL
PLZF	NULL
genes	NULL
.	NULL
``	NULL

PLZF	NULL
has	NULL
some	NULL
homology	NULL
with	NULL
the	NULL
zinc	NULL
finger	NULL
gene	NULL
MZFI	NULL
and	NULL
is	NULL
a	NULL
putative	NULL
transcription	NULL
factor	NULL
preferentially	NULL
expressed	NULL
by	NULL
myeloid	NULL
cells	NULL
.	NULL
``	NULL

Although	NULL
the	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
was	NULL
initially	NULL
cloned	NULL
from	NULL
a	NULL
case	NULL
of	NULL
APL	NULL
,	NULL
our	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
patient	NULL
with	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
did	NULL
not	NULL
have	NULL
features	NULL
of	NULL
APL	NULL
.	NULL

*	NULL
``	NULL
***	NULL
Morphologically	NULL
,	NULL
this	NULL
patient	NULL
was	NULL
classified	NULL
as	NULL
M2	NULL
by	NULL
FAB	NULL
criteria	NULL
and	NULL
had	NULL
10	NULL
%	NULL
promyelocytes	NULL
in	NULL
the	NULL
BM	NULL
.	NULL

The	NULL
patient	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
chemotherapy	NULL
,	NULL
nor	NULL
did	NULL
the	NULL
patient	NULL
's	NULL
cells	NULL
respond	NULL
to	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

254	NULL
ATRA	NULL
in	NULL
vitro	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
is	NULL
intriguing	NULL
that	NULL
the	NULL
patient	NULL
displayed	NULL
a	NULL
moderate	NULL
bleeding	NULL
diathesis	NULL
.	NULL

Why	NULL
patients	NULL
with	NULL
the	NULL
PLZF/RARa	NULL
transcript	NULL
arising	NULL
from	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
fail	NULL
to	NULL
respond	NULL
to	NULL
ATRA	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
ATRA-responsive	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
patients	NULL
with	NULL
PML/RARa	NULL
fusion	NULL
product	NULL
,	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

The	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemias	NULL
described	NULL
in	NULL
this	NULL
report	NULL
received	NULL
various	NULL
remission-induction	NULL
therapies	NULL
,	NULL
primarily	NULL
on	NULL
SWOG	NULL
treatment	NULL
studies	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
and	NULL
because	NULL
of	NULL
the	NULL
limited	NULL
number	NULL
of	NULL
cases	NULL
,	NULL
we	NULL
can	NULL
not	NULL
make	NULL
definitive	NULL
statements	NULL
regarding	NULL
prognosis	NULL
.	NULL

In	NULL
general	NULL
,	NULL
the	NULL
outcomes	NULL
of	NULL
our	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
were	NULL
comparable	NULL
with	NULL
that	NULL
expected	NULL
for	NULL
AML	NULL
patients	NULL
treated	NULL
with	NULL
daunorubicin	NULL
and	NULL
cytosine	NULL
arabinoside	NULL
,	NULL
with	NULL
a	NULL
median	NULL
survival	NULL
of	NULL
30	NULL
months	NULL
.	NULL

However	NULL
,	NULL
several	NULL
of	NULL
the	NULL
myeloid/NK	NULL
acute	NULL
leukemia	NULL
cases	NULL
had	NULL
an	NULL
aggressive	NULL
clinical	NULL
course	NULL
(	NULL
cases	NULL
2	NULL
,	NULL
8	NULL
,	NULL
and	NULL
14	NULL
;	NULL
Table	NULL
1	NULL
)	NULL
with	NULL
no	NULL
response	NULL
to	NULL
standard	NULL
AML	NULL
induction	NULL
chemotherapy	NULL
.	NULL

The	NULL
blasts	NULL
in	NULL
two	NULL
of	NULL
these	NULL
three	NULL
cases	NULL
(	NULL
cases	NULL
2	NULL
and	NULL
14	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
displayed	NULL
high	NULL
levels	NULL
of	NULL
NK	NULL
cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Although	NULL
the	NULL
therapeutic	NULL
responsiveness	NULL
of	NULL
acute	NULL
myeloid/NK	NULL
cell	NULL
acute	NULL
leukemia	NULL
must	NULL
be	NULL
determined	NULL
in	NULL
larger	NULL
studies	NULL
of	NULL
uniformly	NULL
treated	NULL
patients	NULL
,	NULL
these	NULL
initial	NULL
data	NULL
suggest	NULL
that	NULL
more	NULL
effective	NULL
treatment	NULL
regimens	NULL
may	NULL
be	NULL
required	NULL
for	NULL
this	NULL
unique	NULL
group	NULL
of	NULL
acute	NULL
leukemia	NULL
patients	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
the	NULL
following	NULL
SWOG	NULL
Study	NULL
Coordinators	NULL
:	NULL
Dr	NULL
James	NULL
Weick	NULL
,	NULL
SWOG	NULL
8600	NULL
;	NULL
and	NULL
Dr	NULL
James	NULL
Godwin	NULL
,	NULL
SWOG	NULL
9031	NULL
;	NULL
F.R.A	NULL
.	NULL

coordinated	NULL
SWOG	NULL
9034	NULL
.	NULL

They	NULL
also	NULL
thank	NULL
the	NULL
SWOG	NULL
Cytogenetics	NULL
Working	NULL
Group	NULL
for	NULL
review	NULL
of	NULL
submitted	NULL
karyotypes	NULL
;	NULL
Susan	NULL
Allen	NULL
of	NULL
the	NULL
ECOG	NULL
Data	NULL
Management	NULL
Office	NULL
and	NULL
Peter	NULL
Cassileth	NULL
,	NULL
Study	NULL
Chair	NULL
for	NULL
ECOG	NULL
study	NULL
EST-3489	NULL
(	NULL
SWOG	NULL
9034	NULL
)	NULL
,	NULL
for	NULL
providing	NULL
data	NULL
on	NULL
the	NULL
9034	NULL
patients	NULL
;	NULL
Dr	NULL
Stanley	NULL
L.	NULL
Schrier	NULL
of	NULL
Stanford	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
(	NULL
Hematology	NULL
)	NULL
(	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
Carolyn	NULL
Mulgrew	NULL
of	NULL
Cleveland	NULL
Clinic	NULL
(	NULL
Cleveland	NULL
,	NULL
OH	NULL
)	NULL
,	NULL
and	NULL
Alnida	NULL
Ngare	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Michigan	NULL
HEM/ONC	NULL
Protocol	NULL
Office	NULL
(	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
for	NULL
supplying	NULL
important	NULL
clinical	NULL
information	NULL
;	NULL
Dr	NULL
Kathy	NULL
Foucar	NULL
(	NULL
UNM	NULL
)	NULL
for	NULL
independent	NULL
review	NULL
of	NULL
the	NULL
morphologic	NULL
and	NULL
cytochemical	NULL
features	NULL
of	NULL
myeloid/NK	NULL
precursor	NULL
cell	NULL
acute	NULL
leukemia	NULL
cases	NULL
;	NULL
Loretta	NULL
Kanapilly-Chavez	NULL
(	NULL
UNM	NULL
)	NULL
,	NULL
Larry	NULL
C.	NULL
Seamer	NULL
(	NULL
UNM	NULL
)	NULL
,	NULL
Virginia	NULL
A.	NULL
Guptill	NULL
(	NULL
University	NULL
of	NULL
Arizona	NULL
,	NULL
Tuc-son	NULL
)	NULL
and	NULL
Alex	NULL
Chen	NULL
(	NULL
Mount	NULL
Sinai	NULL
Hospital	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
for	NULL
excellent	NULL
technical	NULL
support	NULL
;	NULL
and	NULL
Sheryl	NULL
Curtin	NULL
for	NULL
expert	NULL
manuscript	NULL
preparation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bennett	NULL
JM	NULL
,	NULL
Catovsky	NULL
D	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Galton	NULL
DAG	NULL
,	NULL
Gralnick	NULL
HR	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
Proposals	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
the	NULL
acute	NULL
leukemias	NULL
(	NULL
FAB	NULL
cooperative	NULL
group	NULL
)	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
33:451	NULL
,	NULL
1976	NULL
2	NULL
.	NULL

Bennett	NULL
JM	NULL
,	NULL
Catovsky	NULL
D	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Galton	NULL
DAG	NULL
,	NULL
Gralnick	NULL
HR	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
A	NULL
variant	NULL
form	NULL
of	NULL
acute	NULL
hypergranular	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
44:169	NULL
,	NULL
1980	NULL
3	NULL
.	NULL

Bennett	NULL
JM	NULL
,	NULL
Catovsky	NULL
D	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
Criteria	NULL
for	NULL
the	NULL
diagnosis	NULL
of	NULL
acute	NULL
leukemia	NULL
of	NULL
megakaryocytic	NULL
lineage	NULL
(	NULL
M7	NULL
)	NULL
:	NULL
A	NULL
report	NULL
of	NULL
the	NULL
French-American-British	NULL
cooperative	NULL
group	NULL
.	NULL

Ann	NULL
Intern	NULL
Med	NULL
103:460	NULL
,	NULL
1985	NULL
4	NULL
.	NULL

Bennett	NULL
JM	NULL
,	NULL
Catovsky	NULL
D	NULL
,	NULL
Daniel	NULL
MT	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Galton	NULL
DAG	NULL
,	NULL
Gralnick	NULL
HR	NULL
,	NULL
Sultan	NULL
C	NULL
:	NULL
Proposal	NULL
for	NULL
revised	NULL
criteria	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Ann	NULL
Intern	NULL
Med	NULL
103:620	NULL
,	NULL
1985	NULL
5	NULL
.	NULL

Knowles	NULL
DM	NULL
,	NULL
Chadburn	NULL
A	NULL
,	NULL
Inghirami	NULL
G	NULL
:	NULL
Immunophenotypic	NULL
markers	NULL
useful	NULL
in	NULL
the	NULL
diagnosis	NULL
and	NULL
classification	NULL
of	NULL
hematopoietic	NULL
SCOTT	NULL
ET	NULL
AL	NULL
neoplasms	NULL
,	NULL
in	NULL
Knowles	NULL
DM	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
Neoplastic	NULL
Hematopathology	NULL
,	NULL
Bal-timore	NULL
,	NULL
MD	NULL
,	NULL
Williams	NULL
and	NULL
Wilkins	NULL
,	NULL
1992	NULL
,	NULL
p	NULL
73	NULL
6	NULL
.	NULL

Willman	NULL
CL	NULL
,	NULL
Whittaker	NULL
MH	NULL
:	NULL
The	NULL
molecular	NULL
biology	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

Clin	NULL
Lab	NULL
Med	NULL
10:769	NULL
,	NULL
1990	NULL
7	NULL
.	NULL

Griffin	NULL
JD	NULL
,	NULL
Davis	NULL
R	NULL
,	NULL
Nelson	NULL
DA	NULL
,	NULL
Davey	NULL
FR	NULL
,	NULL
Mayer	NULL
RJ	NULL
,	NULL
Schiffer	NULL
C	NULL
,	NULL
McIntyre	NULL
OR	NULL
,	NULL
Bloomfield	NULL
CD	NULL
:	NULL
Use	NULL
of	NULL
surface	NULL
marker	NULL
analysis	NULL
to	NULL
predict	NULL
outcome	NULL
of	NULL
adult	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
.	NULL

Blood	NULL
68:1232	NULL
,	NULL
1986	NULL
8	NULL
.	NULL

Solary	NULL
E	NULL
,	NULL
Casasnovas	NULL
R-O	NULL
,	NULL
Campos	NULL
L	NULL
,	NULL
Bene	NULL
M-C	NULL
,	NULL
Faure	NULL
G	NULL
,	NULL
Maingon	NULL
P	NULL
,	NULL
Falkenrodt	NULL
A	NULL
,	NULL
Lenormand	NULL
B	NULL
,	NULL
Genetet	NULL
N	NULL
,	NULL
GEIL	NULL
:	NULL
Surface	NULL
markers	NULL
in	NULL
adult	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
:	NULL
correlation	NULL
of	NULL
CD19*	NULL
,	NULL
CD34*	NULL
and	NULL
CD14*/Dr-phenotypes	NULL
with	NULL
shorter	NULL
survival	NULL
.	NULL

Leukemia	NULL
6:393	NULL
,	NULL
1992	NULL
9	NULL
.	NULL

Lee	NULL
EJ	NULL
,	NULL
Yang	NULL
J	NULL
,	NULL
Leavitt	NULL
RD	NULL
,	NULL
Testa	NULL
JR	NULL
,	NULL
Civin	NULL
CL	NULL
,	NULL
Forrest	NULL
A	NULL
,	NULL
Schiffer	NULL
CA	NULL
:	NULL
The	NULL
significance	NULL
of	NULL
CD34	NULL
and	NULL
TdT	NULL
determinations	NULL
in	NULL
patients	NULL
with	NULL
untreated	NULL
de	NULL
novo	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
.	NULL

J	NULL
Clin	NULL
Oncol	NULL
6:1203	NULL
,	NULL
1992	NULL
10	NULL
.	NULL

Machnicki	NULL
JL	NULL
and	NULL
Bloomfeild	NULL
CD	NULL
:	NULL
Clinical	NULL
significance	NULL
of	NULL
the	NULL
cytogenetics	NULL
of	NULL
acute	NULL
leukemia	NULL
.	NULL

Oncology	NULL
4:23	NULL
,	NULL
1990	NULL
11	NULL
.	NULL

Miller	NULL
WH	NULL
,	NULL
Kakizuka	NULL
A	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Warrell	NULL
RP	NULL
Jr	NULL
,	NULL
Delblasio	NULL
A	NULL
,	NULL
Levine	NULL
K	NULL
,	NULL
Evans	NULL
RM	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
:	NULL
Reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
for	NULL
the	NULL
rearranged	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
clarifies	NULL
diagnosis	NULL
and	NULL
detects	NULL
minimal	NULL
residual	NULL
disease	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:2694	NULL
,	NULL
1992	NULL
12	NULL
.	NULL

Haber	NULL
DA	NULL
:	NULL
Multidrug	NULL
resistance	NULL
(	NULL
MDR	NULL
1	NULL
)	NULL
in	NULL
leukemia	NULL
:	NULL
Is	NULL
it	NULL
time	NULL
to	NULL
test	NULL
?	NULL

Blood	NULL
79295	NULL
,	NULL
1992	NULL
13	NULL
.	NULL

Willman	NULL
CL	NULL
:	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
hematologic	NULL
speci-mens	NULL
,	NULL
in	NULL
Knowles	NULL
DM	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
Neoplastic	NULL
Hematopathology	NULL
,	NULL
Balti-more	NULL
,	NULL
MD	NULL
,	NULL
Williams	NULL
and	NULL
Wilkins	NULL
,	NULL
1992	NULL
,	NULL
p	NULL
169	NULL
14	NULL
.	NULL

Foucar	NULL
K	NULL
,	NULL
Chen	NULL
I-M	NULL
,	NULL
Crago	NULL
S	NULL
:	NULL
Organization	NULL
and	NULL
operation	NULL
of	NULL
a	NULL
flow	NULL
cytometric	NULL
immunophenotyping	NULL
laboratory	NULL
.	NULL

Semin	NULL
Diagn	NULL
Pathol	NULL
6:13	NULL
,	NULL
1989	NULL
15	NULL
.	NULL

Seabright	NULL
M	NULL
:	NULL
A	NULL
rapid	NULL
banding	NULL
technique	NULL
for	NULL
human	NULL
chromo-somes	NULL
.	NULL

Lancet	NULL
IL	NULL
:	NULL
971	NULL
,	NULL
1971	NULL
16	NULL
.	NULL

Harden	NULL
DG	NULL
,	NULL
Klinger	NULL
HP	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
An	NULL
International	NULL
System	NULL
for	NULL
Human	NULL
Cytogenetic	NULL
Nomenclature	NULL
.	NULL

Basel	NULL
,	NULL
Switzerland	NULL
,	NULL
Karger	NULL
Basel	NULL
,	NULL
1985	NULL
17	NULL
.	NULL

Mitleman	NULL
F	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
Guidelines	NULL
for	NULL
cancer	NULL
cytogenetics	NULL
,	NULL
supplement	NULL
to	NULL
an	NULL
international	NULL
system	NULL
for	NULL
human	NULL
cytogenetic	NULL
nomenclature	NULL
.	NULL

Basel	NULL
,	NULL
Switzerland	NULL
,	NULL
Karger	NULL
Basel	NULL
,	NULL
1991	NULL
18	NULL
.	NULL

Kern	NULL
WF	NULL
,	NULL
Spier	NULL
CM	NULL
,	NULL
Hanneman	NULL
EH	NULL
,	NULL
Miller	NULL
TP	NULL
,	NULL
Matzner	NULL
M	NULL
,	NULL
Grogan	NULL
TM	NULL
:	NULL
Neural	NULL
cell	NULL
adhesion	NULL
molecule-positive	NULL
peripheral	NULL
T-cell	NULL
lymphoma	NULL
:	NULL
A	NULL
rare	NULL
variant	NULL
with	NULL
a	NULL
propensity	NULL
for	NULL
unusual	NULL
sites	NULL
of	NULL
involvement	NULL
.	NULL

Blood	NULL
79:2432	NULL
,	NULL
1992	NULL
19	NULL
.	NULL

Chomeynski	NULL
P	NULL
,	NULL
Sacchi	NULL
N	NULL
:	NULL
Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Analytical	NULL
Biochemistry	NULL
162:156	NULL
,	NULL
1987	NULL
20	NULL
.	NULL

Biondi	NULL
A	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Pandolfi	NULL
PP	NULL
,	NULL
Rossi	NULL
V	NULL
,	NULL
Giudici	NULL
G	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Pogliani	NULL
EM	NULL
,	NULL
Lanzi	NULL
EM	NULL
,	NULL
Mandelli	NULL
F	NULL
,	NULL
Masera	NULL
G	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Molecular	NULL
monitoring	NULL
of	NULL
the	NULL
myl/retinoic	NULL
acid	NULL
receptor-a	NULL
fusion	NULL
gene	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Blood	NULL
80:492	NULL
,	NULL
1992	NULL
21	NULL
.	NULL

Pandolfi	NULL
PP	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Zangrilli	NULL
D	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Diverio	NULL
D	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Rambaldi	NULL
A	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Roch-ette-Egly	NULL
C	NULL
,	NULL
Gaube	NULL
M-P	NULL
,	NULL
Chambon	NULL
P	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Genomic	NULL
variability	NULL
and	NULL
alternative	NULL
splicing	NULL
generate	NULL
multiple	NULL
PML/RARa	NULL
transcripts	NULL
that	NULL
encode	NULL
aberrant	NULL
PML	NULL
proteins	NULL
and	NULL
PML/RARa	NULL
isoforms	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

EMBO	NULL
11:1397	NULL
,	NULL
1992	NULL
22	NULL
.	NULL

Noonan	NULL
KE	NULL
,	NULL
Beck	NULL
C	NULL
,	NULL
Holzmayer	NULL
TA	NULL
,	NULL
Chin	NULL
JE	NULL
,	NULL
Chin	NULL
JE	NULL
,	NULL
Wunder	NULL
JS	NULL
,	NULL
Andrulis	NULL
IL	NULL
,	NULL
Gazdar	NULL
AF	NULL
,	NULL
Willman	NULL
CL	NULL
,	NULL
Griffith	NULL
B	NULL
,	NULL
Von	NULL
Hoff	NULL
DD	NULL
,	NULL
Roninson	NULL
IB	NULL
:	NULL
Quantitative	NULL
analysis	NULL
of	NULL
MDR1	NULL
(	NULL
multidrug	NULL
resistance	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
tumors	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
87:7160	NULL
,	NULL
1990	NULL
23	NULL
.	NULL

Chen	NULL
S	NULL
,	NULL
Brand	NULL
NJ	NULL
,	NULL
Chen	NULL
A	NULL
,	NULL
Chen	NULL
S-J	NULL
,	NULL
Tong	NULL
J-H	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Waxman	NULL
S	NULL
,	NULL
Zelent	NULL
A	NULL
:	NULL
Fusion	NULL
between	NULL
a	NULL
novel	NULL
Kruppel-like	NULL
zinc	NULL
finger	NULL
gene	NULL
and	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-a	NULL
locus	NULL
due	NULL
to	NULL
a	NULL
variant	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

MYELOID/NATURAL	NULL
KILLER	NULL
CELL	NULL
ACUTE	NULL
LEUKEMIA	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
associated	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
.	NULL

EMBO	NULL
12:1161	NULL
,	NULL
1993	NULL
24	NULL
.	NULL

Chen	NULL
SX	NULL
,	NULL
Zelent	NULL
A	NULL
,	NULL
Tong	NULL
JH	NULL
,	NULL
Yu	NULL
HQ	NULL
,	NULL
Wang	NULL
ZY	NULL
,	NULL
Detre	NULL
J	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Waxman	NULL
S	NULL
,	NULL
Chen	NULL
Z	NULL
:	NULL
Rearrangements	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
alpha	NULL
and	NULL
promyelocytic	NULL
leukemia	NULL
zinc	NULL
finger	NULL
genes	NULL
resulting	NULL
from	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q23	NULL
;	NULL
q21	NULL
)	NULL
in	NULL
a	NULL
patient	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
91:2260	NULL
,	NULL
1993	NULL
25	NULL
.	NULL

Breitman	NULL
T	NULL
,	NULL
Collins	NULL
SJ	NULL
,	NULL
Keene	NULL
B	NULL
:	NULL
Terminal	NULL
differentiation	NULL
of	NULL
human	NULL
promyelocytic	NULL
leukemic	NULL
cells	NULL
in	NULL
primary	NULL
culture	NULL
in	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Blood	NULL
57:1000	NULL
,	NULL
1981	NULL
26	NULL
.	NULL

Breitman	NULL
TR	NULL
,	NULL
Selonick	NULL
SE	NULL
,	NULL
Collins	NULL
SJ	NULL
:	NULL
Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
77:2936	NULL
,	NULL
1980	NULL
27	NULL
.	NULL

Whalen	NULL
MM	NULL
,	NULL
Roshi	NULL
RN	NULL
,	NULL
Bankhurst	NULL
AD	NULL
:	NULL
Effects	NULL
of	NULL
pertussis	NULL
toxin	NULL
treatment	NULL
on	NULL
human	NULL
natural	NULL
killer	NULL
cell	NULL
function	NULL
.	NULL

Immunology	NULL
76:402	NULL
,	NULL
1992	NULL
28	NULL
.	NULL

Sever	NULL
CE	NULL
,	NULL
Whalen	NULL
M	NULL
,	NULL
Chen	NULL
I-M	NULL
,	NULL
Doshi	NULL
R	NULL
,	NULL
Bankhurst	NULL
A	NULL
,	NULL
McConnell	NULL
T	NULL
,	NULL
Willman	NULL
CL	NULL
:	NULL
A	NULL
new	NULL
human	NULL
natural	NULL
killer	NULL
leukemia	NULL
cell	NULL
line	NULL
with	NULL
a	NULL
novel	NULL
complex	NULL
translocation	NULL
:	NULL
Functional	NULL
and	NULL
cytogenetic	NULL
characterization	NULL
.	NULL

Leukemia	NULL
(	NULL
in	NULL
press	NULL
)	NULL
29	NULL
.	NULL

Cosentino	NULL
LM	NULL
,	NULL
Cathcart	NULL
MK	NULL
:	NULL
A	NULL
multi-step	NULL
isolation	NULL
scheme	NULL
for	NULL
obtaining	NULL
CD16*	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
Methods	NULL
103:195	NULL
,	NULL
1987	NULL
30	NULL
.	NULL

Ling	NULL
NR	NULL
,	NULL
Bishop	NULL
S	NULL
,	NULL
Jefferis	NULL
R	NULL
:	NULL
Use	NULL
of	NULL
antibody-coated	NULL
red	NULL
cells	NULL
for	NULL
the	NULL
sensitive	NULL
detection	NULL
of	NULL
antigen	NULL
and	NULL
in	NULL
rosette	NULL
tests	NULL
for	NULL
cells	NULL
bearing	NULL
surface	NULL
immunoglobulins	NULL
.	NULL

J	NULL
Immunol	NULL
Methods	NULL
15:279	NULL
,	NULL
1977	NULL
31	NULL
.	NULL

Kaplan	NULL
EL	NULL
,	NULL
Meier	NULL
P	NULL
:	NULL
Nonparametric	NULL
estimation	NULL
from	NULL
incomplete	NULL
observations	NULL
.	NULL

J	NULL
Amer	NULL
Stat	NULL
Assoc	NULL
53:457	NULL
,	NULL
1958	NULL
32	NULL
.	NULL

De	NULL
Rossi	NULL
G	NULL
,	NULL
Avvisati	NULL
G	NULL
,	NULL
Coluzzi	NULL
S	NULL
,	NULL
Fenu	NULL
S	NULL
,	NULL
LoCace	NULL
F	NULL
,	NULL
Lopez	NULL
M	NULL
,	NULL
Nanni	NULL
M	NULL
,	NULL
Pasqualetti	NULL
D	NULL
,	NULL
Mandelli	NULL
F	NULL
:	NULL
Immunological	NULL
definition	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
FAB	NULL
M3	NULL
)	NULL
:	NULL
A	NULL
study	NULL
of	NULL
39	NULL
cases	NULL
.	NULL

Eur	NULL
J	NULL
Haematol	NULL
45:168	NULL
,	NULL
1990	NULL
33	NULL
.	NULL

Lanier	NULL
LL	NULL
,	NULL
Testi	NULL
R	NULL
,	NULL
Bind	NULL
]	NULL
J	NULL
,	NULL
Phillips	NULL
JH	NULL
:	NULL
Identity	NULL
of	NULL
Leu-19	NULL
(	NULL
CD56	NULL
)	NULL
leukocyte	NULL
differentiation	NULL
antigen	NULL
and	NULL
neural	NULL
cell	NULL
adhesion	NULL
molecule	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
169:2233	NULL
,	NULL
1989	NULL
34	NULL
.	NULL

Nitta	NULL
T	NULL
,	NULL
Yagita	NULL
H	NULL
,	NULL
Sato	NULL
K	NULL
,	NULL
Okumura	NULL
K	NULL
:	NULL
Involvement	NULL
of	NULL
CD56	NULL
(	NULL
NKH-1/Leu-19	NULL
Antigen	NULL
)	NULL
as	NULL
an	NULL
adhesion	NULL
molecule	NULL
in	NULL
natural	NULL
killer-target	NULL
cell	NULL
interaction	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
170:1757	NULL
,	NULL
1989	NULL
35	NULL
.	NULL

Ritz	NULL
J	NULL
,	NULL
Schmidt	NULL
RE	NULL
,	NULL
Michon	NULL
J	NULL
,	NULL
Hercend	NULL
T	NULL
,	NULL
Schlossman	NULL
SF	NULL
:	NULL
Characterization	NULL
of	NULL
functional	NULL
surface	NULL
structures	NULL
on	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Adv	NULL
Immunol	NULL
42:181	NULL
,	NULL
1988	NULL
36	NULL
.	NULL

Arnaout	NULL
MA	NULL
:	NULL
Structure	NULL
and	NULL
function	NULL
of	NULL
the	NULL
leukocyte	NULL
adhesion	NULL
molecules	NULL
CD11/CD18	NULL
.	NULL

Blood	NULL
75:1037	NULL
,	NULL
1990	NULL
37	NULL
.	NULL

Heim	NULL
S	NULL
,	NULL
Mitelman	NULL
F	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Acute	NULL
nonlymphocytic	NULL
leukemia	NULL
,	NULL
in	NULL
Cancer	NULL
Cytogenetics	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
Liss	NULL
,	NULL
1987	NULL
,	NULL
p	NULL
65	NULL
38	NULL
.	NULL

Warrell	NULL
RP	NULL
Jr	NULL
,	NULL
Frankel	NULL
SR	NULL
,	NULL
Miller	NULL
WH	NULL
Jr	NULL
,	NULL
Scheinbert	NULL
DA	NULL
,	NULL
Itri	NULL
LM	NULL
,	NULL
Hittelman	NULL
WN	NULL
,	NULL
Vyas	NULL
R	NULL
,	NULL
Andreeff	NULL
M	NULL
,	NULL
Tafuri	NULL
A	NULL
,	NULL
Jakubowski	NULL
A	NULL
,	NULL
Gabrilove	NULL
J	NULL
,	NULL
Gordon	NULL
MS	NULL
,	NULL
Dmitrovsky	NULL
E	NULL
:	NULL
Differentiation	NULL
therapy	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
ALL-Trans-Retinoic	NULL
acid	NULL
)	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
324:1385	NULL
,	NULL
1991	NULL
39	NULL
.	NULL

Chomienne	NULL
C	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Balitrand	NULL
N	NULL
,	NULL
Danie	NULL
MT	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Castaigne	NULL
S	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemias	NULL
.	NULL

IL	NULL
In	NULL
vitro	NULL
studies	NULL
:	NULL
Structure-function	NULL
relationship	NULL
.	NULL

Blood	NULL
76:1710	NULL
,	NULL
1990	NULL
40	NULL
,	NULL
Chen	NULL
S-J	NULL
,	NULL
Zhu	NULL
Y-J	NULL
,	NULL
Tong	NULL
J-H	NULL
,	NULL
Dong	NULL
S	NULL
,	NULL
Huang	NULL
W	NULL
,	NULL
Chen	NULL
Y	NULL
,	NULL
Xiang	NULL
W-M	NULL
,	NULL
Zhang	NULL
L	NULL
,	NULL
Li	NULL
X-S	NULL
,	NULL
Qian	NULL
G-Q	NULL
,	NULL
Wang	NULL
Z-Y	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
Larsen	NULL
C-J	NULL
,	NULL
Berger	NULL
R	NULL
:	NULL
;	NULL
Rearrangements	NULL
in	NULL
the	NULL
second	NULL
intron	NULL
of	NULL
the	NULL
255	NULL
RARA	NULL
gene	NULL
are	NULL
present	NULL
in	NULL
a	NULL
large	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
and	NULL
are	NULL
used	NULL
as	NULL
molecular	NULL
marker	NULL
for	NULL
retinoic	NULL
acid-induced	NULL
leukemic	NULL
cell	NULL
differentiation	NULL
.	NULL

Blood	NULL
78:2696	NULL
,	NULL
1991	NULL
41	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Balitrand	NULL
N	NULL
,	NULL
deThe	NULL
H	NULL
,	NULL
Dejean	NULL
A	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Chomienne	NULL
C	NULL
:	NULL
A	NULL
PML/retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
fusion	NULL
transcript	NULL
is	NULL
constantly	NULL
detected	NULL
by	NULL
RNA-based	NULL
polymerase	NULL
chain	NULL
reaction	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
79:3110	NULL
,	NULL
1992	NULL
42	NULL
.	NULL

Lanier	NULL
LL	NULL
,	NULL
Le	NULL
AM	NULL
,	NULL
Civin	NULL
CI	NULL
,	NULL
Loken	NULL
MR	NULL
,	NULL
Phillips	NULL
JH	NULL
:	NULL
The	NULL
relationship	NULL
of	NULL
CD16	NULL
(	NULL
Leu-11	NULL
)	NULL
and	NULL
Leu-19	NULL
(	NULL
NKH-1	NULL
)	NULL
antigen	NULL
expression	NULL
on	NULL
human	NULL
peripheral	NULL
blood	NULL
NK	NULL
cells	NULL
and	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Immunol	NULL
136:4480	NULL
,	NULL
1986	NULL
43	NULL
.	NULL

Nagler	NULL
A	NULL
,	NULL
Lanier	NULL
LL	NULL
,	NULL
Cwirla	NULL
S	NULL
,	NULL
Phillips	NULL
JH	NULL
:	NULL
Comparative	NULL
studies	NULL
of	NULL
human	NULL
FcRIII-positive	NULL
and	NULL
negative	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
143:3183	NULL
,	NULL
1989	NULL
44	NULL
.	NULL

Robertson	NULL
MJ	NULL
,	NULL
Ritz	NULL
J	NULL
:	NULL
Biology	NULL
and	NULL
clinical	NULL
relevance	NULL
of	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Blood	NULL
76:2421	NULL
,	NULL
1990	NULL
45	NULL
,	NULL
Miller	NULL
JS	NULL
,	NULL
Verfaillie	NULL
C	NULL
,	NULL
McGlave	NULL
P	NULL
:	NULL
The	NULL
generation	NULL
of	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
from	NULL
CD34*/DR~	NULL
primitive	NULL
progenitors	NULL
in	NULL
long-term	NULL
bone	NULL
marrow	NULL
culture	NULL
.	NULL

Blood	NULL
80:2182	NULL
,	NULL
1992	NULL
46	NULL
.	NULL

Jacobs	NULL
R	NULL
,	NULL
Stoll	NULL
M	NULL
,	NULL
Stratmann	NULL
G	NULL
,	NULL
Leo	NULL
R	NULL
,	NULL
Link	NULL
H	NULL
,	NULL
Schmidt	NULL
RE	NULL
:	NULL
CD167	NULL
CD56*	NULL
natural	NULL
killer	NULL
cells	NULL
after	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL

Blood	NULL
79:3239	NULL
,	NULL
1992	NULL
47	NULL
.	NULL

Pandolfi	NULL
F	NULL
,	NULL
Loughran	NULL
TP	NULL
,	NULL
Starkebaum	NULL
G	NULL
,	NULL
Chisesi	NULL
T	NULL
,	NULL
Barbui	NULL
T	NULL
,	NULL
Chan	NULL
WC	NULL
,	NULL
Brouet	NULL
JC	NULL
,	NULL
DeRossi	NULL
G	NULL
,	NULL
McKenna	NULL
RW	NULL
,	NULL
Salsano	NULL
F	NULL
,	NULL
Herrmann	NULL
F	NULL
,	NULL
Vanoostveen	NULL
JW	NULL
,	NULL
Schlimok	NULL
G	NULL
,	NULL
Cafaro	NULL
A	NULL
,	NULL
Zambello	NULL
R	NULL
,	NULL
Garcia	NULL
Rodriguez	NULL
MC	NULL
,	NULL
Geisler	NULL
CH	NULL
,	NULL
Pizzolo	NULL
G	NULL
,	NULL
Steis	NULL
RG	NULL
,	NULL
Brisbane	NULL
JU	NULL
,	NULL
Kadin	NULL
ME	NULL
,	NULL
Mantovovani	NULL
A	NULL
,	NULL
Tagawa	NULL
S	NULL
,	NULL
Fauci	NULL
AS	NULL
,	NULL
Gastl	NULL
G	NULL
,	NULL
Palutke	NULL
M	NULL
,	NULL
Proctor	NULL
SJ	NULL
,	NULL
Pross	NULL
HF	NULL
,	NULL
Mancini	NULL
P	NULL
,	NULL
Aiuti	NULL
F	NULL
,	NULL
Semenzato	NULL
:	NULL
Clinical	NULL
course	NULL
and	NULL
prognosis	NULL
of	NULL
the	NULL
lymphoproliferative	NULL
disease	NULL
of	NULL
granular	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
65:341	NULL
,	NULL
1990	NULL
48	NULL
.	NULL

Sheridan	NULL
W	NULL
,	NULL
Winton	NULL
EF	NULL
,	NULL
Chan	NULL
WC	NULL
,	NULL
Gordon	NULL
DS	NULL
,	NULL
Vogler	NULL
WR	NULL
,	NULL
Phillips	NULL
C	NULL
,	NULL
Bongiovanni	NULL
KF	NULL
,	NULL
Waldmann	NULL
TA	NULL
:	NULL
Leukemia	NULL
of	NULL
non-T	NULL
lineage	NULL
natural	NULL
killer	NULL
cells	NULL
.	NULL

Blood	NULL
72:1701	NULL
,	NULL
1988	NULL
49	NULL
.	NULL

Imamura	NULL
N	NULL
,	NULL
Kusunoki	NULL
Y	NULL
,	NULL
Kawa-Ha	NULL
K	NULL
,	NULL
Yumura	NULL
K	NULL
,	NULL
Haha	NULL
J	NULL
,	NULL
Oda	NULL
K	NULL
,	NULL
Aba	NULL
K	NULL
,	NULL
Dohy	NULL
H	NULL
,	NULL
Inada	NULL
T	NULL
,	NULL
Kajihara	NULL
H	NULL
,	NULL
Kuramoto	NULL
A	NULL
:	NULL
Aggressive	NULL
natural	NULL
killer	NULL
cell	NULL
leukemia/lymphoma	NULL
:	NULL
Report	NULL
of	NULL
four	NULL
cases	NULL
and	NULL
review	NULL
of	NULL
the	NULL
literature	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
75:49	NULL
,	NULL
1990	NULL
50	NULL
.	NULL

Loughran	NULL
TP	NULL
:	NULL
Clonal	NULL
diseases	NULL
of	NULL
large	NULL
granular	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
82:1	NULL
,	NULL
1993	NULL
51	NULL
.	NULL

Taniwaki	NULL
M	NULL
,	NULL
Tagawa	NULL
S	NULL
,	NULL
Nishigaki	NULL
H	NULL
,	NULL
Horiike	NULL
S	NULL
,	NULL
Misawa	NULL
S	NULL
,	NULL
Shimazaki	NULL
C	NULL
,	NULL
Maekawa	NULL
T	NULL
,	NULL
Fujii	NULL
H	NULL
,	NULL
Kitani	NULL
T	NULL
,	NULL
Abe	NULL
T	NULL
:	NULL
Chromosomal	NULL
abnormalities	NULL
define	NULL
clonal	NULL
proliferation	NULL
in	NULL
CD3~	NULL
large	NULL
granular	NULL
lymphocyte	NULL
leukemia	NULL
.	NULL

Am	NULL
J	NULL
Hematol	NULL
33:32	NULL
,	NULL
1990	NULL
52	NULL
.	NULL

Van	NULL
Camp	NULL
B	NULL
,	NULL
Durie	NULL
BGM	NULL
,	NULL
Spier	NULL
C	NULL
,	NULL
De	NULL
Waele	NULL
M	NULL
,	NULL
Van	NULL
Riet	NULL
I	NULL
,	NULL
Vela	NULL
E	NULL
,	NULL
Frutiger	NULL
Y	NULL
,	NULL
Richter	NULL
L	NULL
,	NULL
Grogan	NULL
TM	NULL
:	NULL
Plasma	NULL
cells	NULL
in	NULL
multiple	NULL
myeloma	NULL
express	NULL
a	NULL
natural	NULL
killer	NULL
cell-associated	NULL
antigen	NULL
:	NULL
CD56	NULL
(	NULL
NKH-1	NULL
;	NULL
Leu-19	NULL
)	NULL
.	NULL

Blood	NULL
76:377	NULL
,	NULL
1990	NULL
53	NULL
.	NULL

Ikushima	NULL
S	NULL
,	NULL
Yoshihara	NULL
T	NULL
,	NULL
Matsumura	NULL
T	NULL
,	NULL
Misawa	NULL
S-I	NULL
,	NULL
Morioka	NULL
Y	NULL
,	NULL
Hibi	NULL
S	NULL
,	NULL
Imashuku	NULL
S	NULL
:	NULL
Expression	NULL
of	NULL
CDS56/NCAM	NULL
on	NULL
hematopoietic	NULL
malignant	NULL
cells	NULL
.	NULL

A	NULL
useful	NULL
marker	NULL
for	NULL
acute	NULL
monocytic	NULL
and	NULL
megakaryocytic	NULL
leukemias	NULL
,	NULL
Int	NULL
J	NULL
Hematol	NULL
54:395	NULL
,	NULL
1991	NULL
54	NULL
.	NULL

Scott	NULL
AA	NULL
,	NULL
Kopecky	NULL
KJ	NULL
,	NULL
Grogan	NULL
TM	NULL
,	NULL
Head	NULL
DR	NULL
,	NULL
Richter	NULL
LC	NULL
,	NULL
Troy	NULL
FA	NULL
,	NULL
Mullen	NULL
J	NULL
,	NULL
Ye	NULL
J	NULL
,	NULL
Appelbaum	NULL
FR	NULL
,	NULL
Theil	NULL
K	NULL
,	NULL
Willman	NULL
CL	NULL
:	NULL
CD56	NULL
:	NULL
A	NULL
determinant	NULL
of	NULL
extramedullary	NULL
involvement	NULL
in	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
with	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
and/or	NULL
monocytic	NULL
differentiation	NULL
.	NULL

(	NULL
in	NULL
preparation	NULL
)	NULL
55	NULL
.	NULL

Kern	NULL
WF	NULL
,	NULL
Spier	NULL
CM	NULL
,	NULL
Miller	NULL
TP	NULL
,	NULL
Grogan	NULL
TM	NULL
:	NULL
NCAM	NULL
(	NULL
CD56	NULL
)	NULL
-positive	NULL
malignant	NULL
lymphoma	NULL
.	NULL

Leuk	NULL
Lymphoma	NULL
12:1	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

blood	NULL
--	NULL
-	NULL
HLA-DR-	NULL
,	NULL
CD33+	NULL
,	NULL
CD56+	NULL
,	NULL
CD16-	NULL
myeloid/natural	NULL
killer	NULL
cell	NULL
acute	NULL
leukemia	NULL
:	NULL
a	NULL
previously	NULL
unrecognized	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
potentially	NULL
misdiagnosed	NULL
as	NULL
French-American-British	NULL
acute	NULL
myeloid	NULL
leukemia-M3	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
AA	NULL
Scott	NULL
,	NULL
DR	NULL
Head	NULL
,	NULL
KJ	NULL
Kopecky	NULL
,	NULL
FR	NULL
Appelbaum	NULL
,	NULL
KS	NULL
Theil	NULL
,	NULL
MR	NULL
Grever	NULL
,	NULL
IM	NULL
Chen	NULL
,	NULL
MH	NULL
Whittaker	NULL
,	NULL
BB	NULL
Griffith	NULL
and	NULL
JD	NULL
Licht	NULL
A	NULL
_	NULL
g	NULL
``	NULL
JO	NULL
430°	NULL
“	NULL
?	NULL
)	NULL

``	NULL
O19nN	NULL
i	NULL
{	NULL
®	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/84/1/244.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

